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Chapter 1
Introduction
Panic disorder
A J0-year oW wo/ne/i /iac? /i^r/Jra/ pan/c aftoc^: w/i/fe sAoppmg.
cowW nof/orce /7frsW//0 go to rft? same swpermar/:*'?. 77?^  ne.v/ pan/c a/facA: oc-
vv/i//V rfr/Y/Hg a ca/: A ,?enw o/Z/jfe/is^/<?«/•
/V/ From r/7^ /7 on, rne/^ar o/anor/7^r af/ac^ matfe /'/ 7>?7/?os5/7>/£' ro rfn've or go
For some people, anxiety takes the form of panic disorder (PD). Like the case de-
scribed above, persons suffering from PD experience panic attacks. Panic attacks
often come without warning or obvious cause and are marked by fear and symp-
toms like palpitations, dyspnea, chest pain and dizziness. People may worry about
having a future panic attack. Repeated panic attacks lead to anticipatory anxiety.
The person starts to fear and avoid places where panic attacks could occur or where
help will not be available should panic recur. Panic attacks occur frequently and
are sometimes linked to specific situations, such as driving a car as described in
the above case. Several criteria must be met for the diagnosis to be applied (see
box 1 and 2).
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Box 1 Panic attack according to DSM-IV
A discrete period of intense fear or discomfort, in which four (or more) of the following symptoms
developed abruptly and reached a peak within 10 minutes:
1. palpitations, pounding heart, or accelerated heart rate
2. sweating
3. trembling or shaking
4. sensations of shortness of breath or smothering
5. feeling of choking
6. chest pain or discomfort
7. nausea or abdominal distress
8. feeling dizzy, unsteady, lightheaded, or faint
9. derealization (feelings of unreality) or depersonalization (being detached from oneself)
10. fear of losing control or going crazy
11. fear of dying
12. paresthesias (numbness or tingling sensations)
13. chills or hot flushes
Box 2 Panic disorder with agoraphobia according to DSM—IV
• Recurrent unexpected panic attacks
• At least one of the attacks has been followed by 1 month (or more) of one (or more) of
the following:
- persistent concern about having additional attacks
- worry about the implications of the attack or its consequences (e.g., losing control,
having a heart attack, "going crazy")
- a significant change in behavior related to the attacks
• The presence of agoraphobia:
- Anxiety about being in places or situations from which escape might be difficult
(or embarrassing) or in which help may not be available in the event of having
an unexpected or situationally predisposed panic attack or panic-like symptoms.
Agoraphobic fears typically involve characteristic clusters of situations that include
being outside the home alone; being in a crowd or standing in a line; being on a
bridge; and travelling in a bus, train, or automobile. Note: Consider the diagnosis
of specific phobia if the avoidance is limited to one or only a few specific situations,
or social phobia if the avoidance is limited to social situations.
- The situations are avoided (e.g., travel is restricted) or else are endured with marked
distress or with anxiety about having a panic attack or panic—like symptoms, or
require the presence of a companion.
- The anxiety or phobic avoidance is not better accounted for by another mental
disorder.
• The panic attacks are not due to the direct physiological effects of a substance (e.g., a
drug of abuse, a medication) or a general medical condition (e.g., hyperthyroidism).
• The panic attacks are not better accounted for by another mental disorder, such as social
phobia (e.g., occurring on exposure to feared social situations), specific phobia (e.g., on
exposure to a specific phobic situation), obsessive—compulsive disorder (e.g., on exposure
to dirt in someone with an obsession about contamination), posttraumatic stress disorder
(e.g.. in response to stimuli associated with a severe Stressor), or separation anxiety
disorder (e.g., in response to being away from home or close relatives).
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Epidemiology of panic
Panic attacks in the general population are quite frequent. The lifetime prevalence
is estimated at 7% to 15%. The lifetime prevalence of PD is between 1.5% and
2.5%. Twelve month prevalence of PD rates around 1% (Overbeek, Vermetten, &
Griez, 2001). PD occurs almost twice as much in women than in men. The peak
of onset for developing PD is generally around the age of 25 (Wittchen & Essau,
1993; American Psychiatric Association. 1994). Co-occurrence of PD and depres-
sion is very common. Thirty to 60% of PD patients have a comorbid depression
(Weissman et al., 1997). PD is also comorbid with other anxiety disorders (Gois-
man et al., 1994), as well as in other general medical conditions, such as cardiovas-
cular diseases (Fleet, Lavoie, & Beitman, 2000; Griez et al., 2000) and respiratory
disorders (Perna, Bertani, Diaferia, Arancio, & Bellodi, 1994; Spinhoven, Ros,
Westgeest, & Van der Does, 1994; Zandbergen et al., 1991).
It has been repeatedly shown that a strong genetic component is present in PD
(e.g., Hettema, Neale, & Kendler, 2001). Consistent with this hereditary com-
ponent is the presence of other cases of PD in affected families (Coryell, 1997;
Crowe, Noyes, Pauls, & Slymen, 1983; Goldstein, Wickramaratne, Horwath, &
Weissmann, 1997; Hettema et al., 2001; Maier, Lichtermann, Minges, Oehrlein, &
Franke, 1993). The high rate of PD among offspring of a parent with PD suggests
that there may be underlying psychological or biological vulnerability factors to
PD. The factor COT sensitivity may identify subjects with a predisposition to de-
velop panic. Therefore, we examined in the present thesis whether COT sensitivity
is a marker of a vulnerability to PD. Furthermore, the psychological factor anxiety
sensitivity and the physiological factor respiratory pathology are hypothesized to
be important factors that might be transmitted in PD families. Hence, the focus of
this thesis is to investigate whether anxiety sensitivity and respiratory pathology
are vulnerability factors to PD.
Carbon dioxide and panic
Panic attacks are the core phenomenon in the clinical picture of PD. Historically,
one was looking for a method to reduce panic attacks in PD patients by using an
inhalation of CO2 enriched air as exposure to internal stimuli. But instead, an
experimental model emerged building on the unexpected finding of CO2 enriched
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air inducing rather than decreasing anxiety symptoms. In experiments, subjects
inhaled different percentages of CO2 enriched air, like the 5% (Gorman et al.,
1984) or the 7% COi condition (Gorman et al., 1988). At the same time, Griez
and Van den Hout also worked with carbon dioxide inhalation. They used a single
breath inhalation of 35% COi and 65% Oi. To their surprise they found that
35% CO2 appeared to trigger anxiety symptoms rather than reducing it (Griez,
Lousberg, Van den Hout, & Van der Molen, 1987; Van den Hout & Griez, 1984).
Over the years it has become clear that 35% CO2 induces panic-like symptoms and
does not block anxious feelings as previously believed (Verbürg, Perna, & Griez,
2001). Inhalation of 35% CO2 induces physical symptoms that mimic a panic
attack, and in susceptible patients leads to subjective anxiety as well. Through
a self-administration mask, subjects receive one vital capacity inhalation of 35%
CO2 and 65% OT which triggers a very short-lived panic attack in the laboratory.
Therefore, the CO2 challenge has been used as a laboratory model to study PD
(Verbürg et al., 2001).
This CO2 model for panic could give more insight into the mechanisms that
cause anxiety in vulnerable individuals. Several studies have been carried out to
examine this idea. In one study, 12 PD patients and 11 healthy controls inhaled one
vital capacity of 35% CO2. It was found that PD patients were more anxious and
experienced more panic symptoms than controls (Griez et al., 1987). Others have
found the same result (Fyer et al., 1987; Perna et al., 1994). The CO2 vulnerability
of PD patients was not a matter of an already present high baseline anxiety (Griez,
De Loof, Pols, Zandbergen, & Lousberg, 1990).
A next step was to investigate whether the challenge differentiates PD patients
from other anxiety disorder patients. It has been shown that PD patients were more
vulnerable to a 35% CO2 challenge than patients with obsessive compulsive disor-
der (Griez et al., 1990; Perna, Bertani, Arancio, Ronchi, & Bellodi, 1995), general-
ized anxiety disorder patients (Verbürg, Griez, Meijer, & Pols, 1995a), and subjects
with animal phobia (Verbürg, Griez, & Meijer, 1994). Also, PD patients are more
reactive to a 35% CO2 challenge than patients with mood disorder (Perna, Barbini,
Cocchi, Bertani, & Gasperini, 1995) and other psychiatric disorders (Griez, Zand-
bergen, Pols, & De Loof, 1990). Yet, persons with for example fear of heights or
fear of thunderstorms (situational/natural phenomena phobics) were more vulner-
able to the challenge than controls. Their increase in anxiety was comparable to
that of PD patients (Verbürg et al., 1994). Furthermore, social phobics seem to be
10
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CO2-sensitive as well (Caldirola, Perna, Arancio, Bertani, & Bellodi, 1997). Al-
though social phobics experience significantly more panic symptoms than normal
controls, they were not more anxious (Verbürg, Perna, Bellodi, & Griez, 1998). It
seems that the CO2 sensitivity in social phobics is in between that of healthy vol-
unteers and PD patients (Schuers et al„ personal communication). Besides, others
found that PD patients were more sensitive to CO2 than patients with social phobia
or normal subjects (Papp et al., 1993). Overall, the 35% COT challenge appears to
be a specific marker for a spectrum of conditions related to panic.
It is still unknown how CO2 inhalation exactly induces panic. It was thought
that hyperventilation played a role. Obviously, an inhalation of 35% CO2 a hyper-
capnic gas, induces a strong hyperventilatory response. Hyperventilation can be
defined as rapid and deep breathing in excess of the metabolism resulting in a de-
crease of CO2 in the blood and increased blood acid level (pH). Hyperventilation
results in a state of respiratory alkalosis. The role of hyperventilation as a causal
factor for panic has been investigated in several experiments. The rationale is,
that if hyperventilation causes panic attacks by inducing respiratory alkalosis, then
CO2 inhalation should not induce panic, because CO2 administration increases
ventilation but does not induce alkalosis. This was investigated in PD patients. It
was shown that PD patients did not panic after forced hyperventilation. However,
5% CO2 for 20 minutes did induce panic (Gorman et al., 1984). Furthermore,
it was found that hypocapnia resulting from forced hyperventilation failed to in-
duce any clinically significant anxiety in PD patients or controls (Griez, Zandber-
gen, Lousberg, & Van den Hout, 1988; Zandbergen, Lousberg, Pols, De Loof, &
Griez, 1990). In conclusion, hyperventilation does not causally induce panic. Not
hypocapnia, but an increased CO2 concentration can induce a panic attack (Griez
& Verbürg, 1995). Moreover, it is suggested that hyperventilation is a response to
panic instead of a causal mechanism (Griez & Verbürg. 1995; Hornsveld, Garssen,
Fieldeldij Dop, Van Spiegel, & De Haes, 1996).
Familial loading for PD
The above mentioned studies show that the 35% CO2 challenge induces panic in
PD patients. This knowledge gave rise to a new experimental approach of PD.
Family and twin studies were conducted using the CO2 challenge as a probe to ex-
plore the predisposition to CO2 vulnerability (Bellodi et al., 1998; Coryell, 1997;
11
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Perna, Bertani, Caldirola, & Bellodi, 1996). Results suggest that 35% CO2 hyper-
sensitivity may be a marker of familial loading to PD (Chapter 2).
It has been established that genetic and familial influences play a role in the de-
velopment of PD (Crowe et al., 1983; Goldstein et al., 1994; Kendler. Heath, Mar-
tin, & Eaves, 1986; Skre, Onstad, Torgersen, Lygren, & Kringlen, 1993; Torgersen,
1983, 1988; Weissman, 1993). For example, in one study, 17% of the first-degree
relatives of PD patients had PD compared to 2% of the first-degree relatives of
controls (Crowe et al., 1983). In another study it was found that first-degree rel-
atives of PD patients had an increased risk for developing PD (Goldstein et al.,
1994). Specifically, it seems that children of PD parents may be particularly prone
to develop PD later in life. This is supported by other findings. Firstly, children of
PD patients are at higher risk of having anxiety disorders than children of healthy
control parents (Turner, Beidel, & Costello, 1987). Secondly, during childhood,
children of PD parents had significantly more often internalizing anxiety disorders
than children of parents with animal phobia or healthy control parents (Unnewehr,
Schneider, Florin, & Margraf, 1998). And thirdly, in prospective studies most chil-
dren with an anxiety disorder still suffer from an anxiety disorder later in adulthood
(Newman et al., 1996; Pine, Cohen, Gurley, Brook, & Ma, 1998). Given a relation
between PD of parents and their offspring, it might be suggested that PD parents
transmit a diathesis for PD. One diathesis for the development of PD might be high
anxiety sensitivity. This is discussed in the next section.
Anxiety sensitivity
Anxiety sensitivity (AS) refers to individual differences in the fear of anxiety-
related sensations and the expectation that such sensations can have harmful con-
sequences (Reiss, 1997; Reiss & McNally, 1985). Just as some people are afraid
of spiders, some individuals fear the sensations that accompany anxiety. This con-
struct AS can be measured with the Anxiety Sensitivity Index (ASI) (Peterson &
Reiss, 1992; Reiss, Peterson, Gursky, & McNally, 1986). AS has been proposed
as a risk factor for the development of anxiety disorders, specifically PD (Reiss,
1991).
Besides AS, trait anxiety is also regarded as a vulnerability factor for the de-
12
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velopment of anxiety disorders. While AS and trait anxiety are intercorrelated
(Muris, Schmidt. Merckelbach, & Schouten, 2001), both constructs can be seen
as conceptually different (McNally, 2002). Trait anxiety is a higher order con-
struct that denotes a general tendency to react fearfully to Stressors, whereas AS
is a lower order construct that is viewed as a specific tendency to react fearfully
to one's own anxiety symptoms (McNally, 1999). Some see AS as a facet of trait
anxiety (McNally. 1999).
Several times it has been found that elevated ASI scores and PD are strongly
associated (McNally, 2002). Research in adult populations has provided evidence
that AS is elevated in patients with PD (Reiss, 1991; Taylor, Koch, & McNally,
1992). In this respect, high AS would be considered as a consequence of a person
having had panic attacks. On the other hand, elevated ASI levels were found in
nonclinical subjects (Donnell & McNally, 1990). This indicates that AS can be
acquired from sources other than through direct experience with panic attacks.
Misinformation about for example heart diseases may increase AS in an individual,
as may observational learning. If the fear of anxiety-related symptoms can be
acquired prior to any experience with panic, then AS can be a predisposing factor
for the development of PD. Prospective studies have addressed this idea. Young
nonclinical adults with high ASI scores were five times more likely to develop an
anxiety disorder than young adults with low ASI scores during a 3-year follow-
up. Three out of four subjects who had their first panic attack later on were in
the high ASI group. Moreover, initial ASI scores predicted the frequency and
intensity of panic attacks during the follow-up period (Mailer & Reiss, 1992). In
another study, it was evaluated whether AS predicted the development of anxiety
pathology. A large sample of nonclinical subjects was followed over a 5-week
highly stressful period of time (i.e. military basic training). AS was found to be
predictive of the development of spontaneous panic attacks after controlling for
a history of panic attacks and trait anxiety (Schmidt, Lerew, & Jackson, 1997).
Taken together, these studies suggest that elevated AS is a vulnerability factor for
developing panic.
Prospective studies of AS in nonclinical samples can evaluate the initial inci-
dence of anxiety pathology. The role of AS in the long-term course of anxiety
pathology can be examined in longitudinal studies of clinical samples. In this re-
spect, reduction in AS levels due to treatment should be associated with clinical
improvement. In Chapter 3 to 6, the role of AS will be further discussed.
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Respiratory disorders
Obviously, elevated AS may not be the only risk factor for the development of PD.
Other factors, such as respiratory disorders are also linked to PD. Superficial evi-
dence in favor of a relation between PD and respiratory disorders is that symptoms
of panic attacks show overlap with symptoms seen in patients with respiratory
disorders (Smoller, Pollack, Otto, Rosenbaum, & Kradin, 1996). On the other
hand it is possible that, suffering from pulmonary disorders may increase the risk
of developing PD. Consistent with this hypothesis, the rate of PD was found to be
significantly higher in patients with chronic obstructive pulmonary diseases than in
the general population (Karajgi, Rifkin, Doddi, & Kolli, 1990; Yellowlees, Alpers,
Bowden, Bryant, & Ruffin, 1987). Moreover, PD patients were found to have suf-
fered significantly more from lifetime respiratory disorders than other populations
(Perna et al., 1994; Spinhoven et al., 1994; Zandbergen et al., 1991). Not only in
adults have associations between PD and respiratory disorders been documented.
A study in youth, aged 9-17 years, demonstrated that among anxiety disorders
the strongest association was found between allergy and PD (Kovalenko et al.,
2001). Furthermore, adults who develop PD later in life had a higher childhood
prevalence of respiratory diseases than did obsessive compulsive and eating dis-
order patients (Zandbergen et al., 1991). Even more important, besides the above
mentioned studies on high comorbidity of PD and respiratory disorders, respira-
tory diseases were associated with an increased risk for panic attacks in a large
sample of adults in the general population. This association even persisted af-
ter controlling for sociodemographic characteristics, and comorbidity of physical
and mental disorders (Goodwin & Pine, 2002). Therefore, respiratory disorders
may be a vulnerability factor for the development of PD. Increased awareness of
respiratory disorders, like asthma, as a potential risk factor, is important, because
asthma is one of the most common health problems, with an increasing prevalence
in most developed countries (Steerenberg et al., 2000). Therefore, improving our
understanding of the relation between respiratory pathology and PD is needed. Es-
pecially when considered the facts that both PD (see section familial loading for
PD) and respiratory disorders, like asthma (e.g., Hopper, Hannah, Macaskill, &
Mathews, 1990), run in families. This might have clinical implications. Therefore,
in Chapter 7 the link between PD and respiratory disorders in families will be fur-
ther discussed. It is conceivable that both disorders are the expression of a third
14
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factor that runs in families and predisposes to PD. A familial association between
PD and CO2 hypersensitivity has already been suggested (Coryell, 1997; Perna
et al.. 1996) and an inhalation of 35% CO2 has a strong effect on the respiratory
system. Thus, the study in Chapter 8 presents data on the possible link between
respiratory pathology, CO2 vulnerability and PD.
Outline of the thesis
With the above mentioned frame of reference in mind, the present thesis aims to
elucidate three risk factors to PD. On that account, seven studies were performed
in patients with PD and their first-degree relatives. In Chapter 2 the factor CO2
vulnerability will be discussed. In the following chapters, two factors possible
connected to CO2 vulnerability were examined. First, the cognitive factor AS was
studied (Chapter 3 to 5). Second, the role of the physiological factor respiratory
disorders was investigated (Chapter 7 to 8).
As has been mentioned in the previous sections, the 35% CO2 challenge is used to
provoke paniclike symptoms in a laboratory. It is known that PD patients are more
vulnerable to 35% CO2 than other populations. Aiso, PD runs in families. If there
is a link between CO2 sensitivity and familial loading for PD, then first-degree
relatives of PD patients should be more reactive to CO2 than control participants.
Therefore, the hypothesis that first-degree relatives of PD patients are more re-
active to the CO2 challenge than control participants is tested in Chapter 2. It
was found that being a first-degree relative of a PD patient is an important factor
in CO2 hypersensitivity. The results suggest that CO2 hypersensitivity may be a
marker of a familial vulnerability to PD. However, the nature of this vulnerability
remains unclear. Therefore, possible factors that could be associated with CO2
sensitivity are investigated in the next chapters. First, in Chapter 3 to 5 the factor
AS will be studied.
AS has been proposed as a cognitive risk factor for the development of PD.
Moreover, it is suggested that AS itself has a strong hereditary component. There-
fore, persons who are reactive to the CO2 challenge, i.e. PD patients and their
first-degree relatives, could be highly anxiety sensitive. It has been repeatedly
shown that PD patients have high AS levels. Contrarily, to our knowledge, AS in
first-degree relatives of PD patients has not been investigated. Before turning to
15
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this issue, we examined factors playing a role in being highly anxiety sensitive,
like age and sex. For example, older women could be more afraid of feeling pal-
pitations than young men. Hence, in Chapter 3, it was investigated whether sex
and age influence AS. In Chapter 4, AS in first-degree relatives of PD patients was
studied. Results showed that first-degree relatives of PD patients were more anx-
iety sensitive than control subjects. This particular group of first-degree relatives
was relatively old (mean age of 50 years). Since the peak of onset for PD is around
25, these first-degree relatives will most likely not develop a PD. Under the as-
sumption that high AS is a risk factor for developing PD, it would be interesting to
know if children of PD patients, who are still at risk for developing PD, are highly
anxiety sensitive. Thus, we elaborate on the theme AS in children in Chapter 5.
As a side issue, to further explore AS, SSRI treatment effects on AS in PD patients
were studied in Chapter 6, which is the final chapter on AS in this thesis.
Second, we now elaborate on the physiological factor respiratory pathology.
As reported in the previous section on respiratory disorders, the association be-
tween PD and respiratory disorders has been well documented in several studies.
For example, PD patients have more childhood respiratory disorders than other
populations. Hence, respiratory pathology could be a vulnerability factor for the
development of PD. Furthermore, as noted before, an association between genetic-
familial vulnerability to PD and respiration seems to exist. To further explore the
relation between respiratory disorders and familial loading for PD, we investigated
in Chapter 7 if the lifetime prevalence of respiratory disorders in first-degree rela-
tives of PD patients is higher than in first-degree relatives of patients with another
anxiety disorder than PD.
The inhalation of 35% CO2 has consistently been shown to provoke panic in
PD patients, as reported in the section carbon dioxide and panic. However, not
all PD patients are equally vulnerable to COT. Therefore, in Chapter 8 the hy-
pothesis that specifically PD patients with a history of respiratory disorders are
more vulnerable than PD patients without such a history. More general, a pos-
sible physiological mechanism underlying CO2 vulnerability in PD patients was
investigated.
In the final Chapter 9, the findings will be summarized and discussed. In sum,
this thesis focuses on whether CO2 sensitivity is a marker of the vulnerability to
PD, and whether AS and respiratory pathology are vulnerability factors in PD
patients and their first-degree relatives.
16
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Reactivity to a 35% CO2 challenge in healthy
first-degree relatives of patients with panic
disorder
Background: The effects of a 35% CO2 challenge were examined in healthy first-
degree relatives of panic disorder patients and in healthy control subjects matched
for age and gender.
Methods: One single inhalation of a 35% CO2 / 65% O2 challenge was adminis-
tered to 50 first-degree relatives of panic disorder patients and 50 control subjects.
Results: The first-degree relatives were more reactive to the 35% CO2 challenge
than the control subjects.
Conclusions: These findings indicate that being a member of a family with a panic
disorder patient is, in itself, an important factor in CO2 hypersensitivity among
subjects who have never experienced a panic attack. Both panic disorder patients
and their first-degree relatives have a tendency to be more reactive to the CO2
challenge.
van Beek, N., & Griez, E. (2000). Reactivity to a 35% COi challenge in healthy first-degree relatives
of patients with panic disorder, ß/o/ogi'ca/ Pjyc/i/a/ry' ^7, 830-835.
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Introduction
It has been established that panic attacks can be experimentally elicited by
inhalation (Griez & Verbürg, 1995). The CO2 challenge appears to be sensitive
and specific as regards the induction of panic in panic disorder (PD) patients (Griez
et al., 1990, 1990; Perna et al., 1994). One single vital capacity inhalation of a 35%
CO2 mixture in oxygen provokes a brief, immediate paniclike episode in patients
with PD but does not in control subjects (Griez et al., 1990; Perna et al., 1994).
Thus, PD patients seem to be hypersensitive to a CO2 inhalation. Carbon dioxide
seems to activate specific mechanisms and that may be what predisposes them to
the development of panic (Griez et al., 1990).
As far as predisposing factors are concerned, several studies provide evidence
that familial factors play an important role in PD (Coryell, 1997; Crowe et al.,
1983; Goldstein et al., 1997; Maier et al., 1993). Others suggest a genetic factor
in PD (Torgersen, 1983). It is known that PD runs in families and that PD patients
have a certain tendency to react hypersensitively to CO2. If there is a link between
familial loading for PD and hypersensitivity to CO2, first-degree relatives may also
have a tendency to be hypersensitive to CO2. Our aim, therefore, was to determine
whether first-degree relatives of PD patients are, in fact, more reactive to a 35%
CO2 / 65% O2 challenge than healthy control subjects.
Method
Subjects
Fifty healthy first-degree relatives of PD patients were included in this study (29
men and 21 women; mean age = 30.8 years; SD = 12.08; range 16-63 years),
as were 50 control subjects (29 men and 21 women; mean age = 30.56; SD =
12.31; range 16-63 years). At the time of the challenge, all subjects were healthy
and none had taken any medication that could influence their mental state. The
subjects met the inclusion criteria.
Inclusion criteria were age between 16 and 63 years, absence of any present
or past psychiatric illness, a state of good physical health, and no prior experience
with the CO2 challenge. For PD patients, an additional criterion was a DSM III—R
diagnosis panic disorder, with or without agoraphobia, by at least two experienced
clinicians.
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CO.; challenge in first-degree relatives
A clinical interview about the family was carried out and a clinical history as-
certained in search of the following exclusion criteria: important cardiovascular
history or suspicion of infarct. cardiomyopathy, cardiac failure, transient ischemic
attack, angina pectoris, cardiac arrythmias or cerebrovascular accident; important
respiratory history, including asthma and lung fibrosis; personal or familial his-
tory of cerebral aneurysm; hypertension with systolic pressure of > 180 mmHg
or diastolic pressure of > 100 mmHg; pregnancy; epilepsy; and noninvalidating
chronic obstructive pulmonary disease. First-degree relatives were also excluded
if they had ever had a panic attack or a hyperventilation attack. Control subjects
were also excluded if they had a first-degree relative with an anxiety disorder or
a depression. At the time of the challenge, none of the subjects had taken any
central acting drugs, including jß-blockers; an occasional exception was made for
incidental use of low doses of benzidiacepines (i.e., single doses equivalent to 5
mg of diazepam) in the past 2 weeks. Subjects were asked to refrain from alcohol
for at least 36 hours, from beverages containing xanthine for at least 8 hours, and
from eating or smoking for at least 2 hours before the test.
Apparatus
For the CO2 challenge, two different gas mixtures were used: compressed air
(placebo) and a mixture of 35% COT / 65% Oi. Both gases were inhaled through
the same self-administration mask. The respirometer connected to the self-ad-
ministration mask measured the gas volume delivered at each inhalation.
Self-administered questionnaires that the subjects filled out included the State-
Trait Anxiety Inventory (STAI-1) (Spielberger, Gorsuch, & Lushere, 1970) for
anxiety state, the Visual Analogue Scale for Anxiety (VAS-A) (Perna et al., 1994)
for subjective anxiety, and the Panic Symptom List, DSM III-R (PSLIII-R) (Pols,
Zandbergen, De Loof, & Griez, 1991) for panic symptoms.
Procedure
Control subjects were recruited either by word of mouth or through advertisements
placed throughout the city of Maastricht. They received a questionnaire that they
filled out before the experiment in order to give the investigators an impression of
their health. If the subject was not healthy, he or she was excluded. The first-
degree relatives were selected from among PD patients referred to the Academic
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Anxiety Center Maastricht for treatment. Because subjects with a psychiatric dis-
order (axis I), panic attacks, or hyperventilation attacks were excluded, the first-
degree relatives were interviewed by an experienced psychiatrist, and the control
subjects by a mental health scientist who used the Mini International Neuropsy-
chiatric Interview, version 4.3 (Sheehan et al., 1994). A panic attack was defined
as a period of intense fear or discomfort and at least four symptoms described in
DSM III—R. A hyperventilation attack was defined as the suspicion that the breath-
ing pattern was fast, deep, disregulated and not related to the physical activity of
the subject. All subjects were tested in a double-blind, random, cross-over de-
sign (with half of the subjects inhaling CO2 first and the other half air) and they
were matched for age and gender. Before the challenge, informed consent was ob-
tained from the subjects. All subjects were paid for participating in the challenge.
Briefly, subjects were informed beforehand that they would inhale two different
gas mixtures containing different percentages of CO2 and Oi, and that during the
challenge they might experience some discomfort, ranging from a few physical
symptoms to a definite sensation of anxiety. The possibility of a panic attack was
not mentioned.
Vital capacity was measured and baseline anxiety assessed with the STAI-1.
The subject then received one vital capacity inhalation of 35% CQ2 / 65% O2 or
compressed air in a randomly assigned order, with an interval of 10 min between
the two inhalations. The researcher made sure that the gas mixture was inhaled
for a period of 4 sec. The test was considered valid only if the subject had inhaled
at least 80% of the previously measured vital capacity. For safety reasons blood
pressure was measured before and after each inhalation. Immediately before and
after each inhalation (air or CO2), anxiety was assessed via the VAS-A and panic
symptoms via the PSL III—R.
Data analyses
The baseline scores of the first-degree relatives, assessed by the STAI-1 and the
VAS-A prior to the first inhalation, were compared with those of the control sub-
jects by means of Student's t-test. Linear regression analysis was performed to
evaluate if baseline anxiety, assessed by the STAI-1, is a predictor of anxiety re-
sponse (i.e., VAS-A score > 25 post-CO^).
To determine whether the COT inhalation, in general, induces more panic
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symptoms than the air inhalation and whether the first-degree relatives report more
panic symptoms (PSL III—R) after inhalation of COT than after inhalation of air
compared with control subjects, a multivariate analysis of variance (MANOVA)
was applied, with group (first-degree relatives vs. control subjects) as between-
subjects factor and moment of inhalation (pre- vs. post-inhalation) and procedure
(CO2 vs. air) as within-subjects factors. The same analysis was used for subjective
anxiety.
A post-COi score of 25 assessed by the VAS-A seemed to be the score that
best discriminated PD patients from control subjects (Verbürg et al., 1998). A
Chi-square analysis was applied to determine whether more first-degree relatives
had a higher or an equal score on the VAS-A after CO2 inhalation compared with
control subjects.
A CÜ2-induced panic attack was defined by an increase of anxiety (VAS-A
> 25) combined with an increase in panic symptomatology. This definition is com-
parable to the one used in previous studies on CO^-induced panic (Pols, Verbürg,
Hauzer, Meijer, & Griez, 1996; Woods, Charney, Delgado, & Heninger, 1990).
Results "
Baseline anxiety
Table 2.1 shows baseline anxiety scores of the subjects.
Table 2.1 Baseline
Baseline anxiety
STAI-1
VAS-A pre-CO:
VAS-A pre-air
anxiety of the subjects before the
First-degree relatives
29.7 ±6 .2
2.4 ±4 .8
3.5 ±5 .9
first inhalation
Control
26.9
3.2
3.6
subjects
±5.0
±5.5
±7.0
Results are expressed as mean ± SD. STAI-1, State-Trait Anxiety Inventory-1; VAS-A, Visual
Analogue Scale for Anxiety.
The mean baseline anxiety score of the first-degree relatives on the STAI-1 was
29.7 (SD = 6.2) versus 26.9 (SD = 5.0) for the control subjects. This represents
a significant difference between the two groups (t(98) = 2.42, p < 0.025). The
first-degree relatives showed more anxiety than the control subjects before the first
inhalation as assessed with the STAI-1. Yet, no significant difference was found
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in anxiety before the first inhalation between the first-degree relatives and the con-
trols as assessed with the VAS-A. The mean VAS-A score before the CO2 inhala-
tion was 2.4 (SD = 4.8) for the first-degree relatives versus 3.2 (SD = 5.5) for
the control subjects (t(98) = -0.76, p = NS). The mean score before the air inhala-
tion was 3.5 (SD = 5.9) for the first-degree relatives versus 3.6 (SD = 7.0) for the
control subjects (t(98) = -0.06, p = NS).
Linear regression analysis revealed that baseline anxiety, using the STAI-1,
did not predict differences between first-degree relatives and control subjects on
the VAS-A score of > 25 post-CCh (R- = 0.073, F(2,31) = 1.23, p = NS).
Panic symptoms
Table 2.2 Panic symptoms of the subjects
Panic symptoms First-degree relatives Control subjects
PSL pre-CO: 0.7 ± 1.2 0.2 ± 5.2
PSL post-CO: 8.0 ± 7.5 5.4 ± 5.2
PSLpre-air 1.0 ±1.7 0.6 ±1 .2
PSL post-air 1.1 ± 1.7 0.6 ±1 .2
Results are expressed as mean ± SD. PSL. Panic Symptom List.
Table 2.2 shows the results of the challenges. A three-way MANOVA showed a
significant main effect for group (F(l,98) = 5.0, p < 0.05), procedure (F(l,98) =
108.3, p < 0.001) and moment of inhalation (F(l,98) = 111.5, p < 0.001). A signif-
icant interaction effect was found for procedure x moment of inhalation (F(l,98)
= 94.3, p < 0.001), indicating that the CO2 inhalation induced significantly more
panic symptoms than the air inhalation. There were no significant interactions
for group x procedure (F(l,98) = 3.9, p = 0.051), group x moment of inhala-
tion (F(l,98) = 3.6, p = 0.061), and group x procedure x moment of inhalation
(F(l,98) = 2.6, p = 0.055), although group x procedure and group x procedure x
moment of inhalation are almost significant. The latter interaction shows that the
CO: inhalation induced more panic symptoms in the first-degree relatives than in
the control subjects.
Subjective anxiety
Results are displayed in Table 2.3.
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Table 2.3 Subjective
Subjective anxiety
anxiety of the subjects
First-degree relatives
CO, challenge in first-degree relatives
Control subjects
VAS-A pre-COi 2.4 ± 4.8 3.2 ± 5.5
VAS-A pre-air 3.5 ± 6.0 3.6 ± 7.0
VAS-A post-CO2 23.8 ±26.1 16.5 ±21.7
VAS-A post-air 3.3 ± 5.8 3.9 ± 6.9
Results are expressed as mean ± SD. VAS-A, Visual Analogue Scale for Anxiety.
A significant main effect was found for procedure (F(l,98) = 53.7, p < 0.001)
and moment of inhalation (F(l,98) = 54.7, p < 0.001). No significant effect was
found for group (F(l,98) = 0.7, p = NS) group x procedure (F(l,98) = 2.8, p
= NS), or group x moment of inhalation (F(l,98) = 2.6, p = NS). Significant
interactions were found for procedure x moment of inhalation (F( 1,98) = 52.7, p <
0.001) and group x procedure x moment of inhalation (F(l,98) = 3.3, p < 0.05).
This indicates that the CCh inhalation induced more subjective anxiety than the
air inhalation, and the last-mentioned interaction shows that the COi inhalation
induced more subjective anxiety in the first-degree relatives than in the control
subjects.
VAS-A post score
Results are shown in Table 2.4.
Table 2.4 Anxiety score > 25 on the VAS-A post-CO: inhalation
Anxiety score First-degree relatives Control subjects
V A C A ^ K , ^ c ™ 49.7 ±17.4 49.5 ±18.7
VAS-A > 25 (mean ± SD) „„ „
range 25-91 range 29-80
Number of subjects who
^ o < u , , c A 22(44%) 12(24%)
scored > 25 on the VAS-A
VAS-A, Visual Analogue Scale for Anxiety
A significant difference was found in the VAS-A score post-CC>2 inhalation be-
tween the first-degree relatives and the control subjects (#~ = 4.46, df = 1, p <
0.05).
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C02~induced panic attacks
A significant difference was found in CCh-induced panic attacks between the first-
degree relatives and the control subjects (£~ = 4.46, df = 1, p < 0.05). Twenty-two
first-degree relatives (44%) and 12 controls (24%) had a panic attack.
Discussion
The results of our study support the idea that first-degree relatives of PD patients
are more responsive to the COi challenge than control subjects. Carbon dioxide
reactivity of first-degree relatives was assessed in three different ways. First, an in-
crease on the VAS-A was measured, indicating CCb-induced subjective anxiety.
Second, PSL III—R symptoms were measured, roughly indicating CO2-induced
autonomic panic symptoms. Also, the number of subjects who had a score higher
than 25 on the VAS-A post-COi inhalation was counted. Finally, the number of
panic attacks was registered. Whatever measurement we took, first-degree rela-
tives clearly appeared more vulnerable to the COi challenge than control subjects.
It therefore seems that both PD patients and their first-degree relatives share some
specific vulnerability to inhalation of COi.
It may be speculated that the first-degree relatives' stronger reaction to the
CO2 challenge compared with the healthy control subjects might have been the
result of a higher baseline anxiety. One way to assess baseline anxiety is to use the
STAI-1. Indeed, the first-degree relatives had a higher STAI-1 score at baseline.
However, baseline anxiety may also be inferred from the VAS-A scale, which was
filled in immediately before the first inhalation. Using the VAS-A, no difference
could be seen between the first-degree relatives and control subjects. In any case,
earlier findings of our group and others have demonstrated that a high baseline
anxiety is not a sufficient condition for COi-triggered anxiety in PD (Perna et al.,
1994), even though it might be a necessary one (Griez et al., 1990). We also found
that linear regression analysis revealed that baseline anxiety did not predict CO2-
induced anxiety.
It may be argued that our first-degree relatives might have experienced isolated
panic attacks earlier in their life, even if they failed to meet the diagnosis of PD.
Indeed, healthy subjects who experience sporadic panic attacks have been reported
to be 35% COi-reactive compared with control subjects without a lifetime history
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of panic attacks (Perna, Gabriele, Caldirola, & Bellodi, 1995). However, in order
to eliminate this type of bias in our study first-degree relatives were very carefully
screened. Any suspicion of a lifetime panic-like or hyperventilation attack was
an explicit criterion for exclusion. It is thus very unlikely that our results can be
explained by unnoticed, subthreshold PD.
Other studies have already suggested that healthy relatives of PD patients may
be more vulnerable to panic-inducing procedures than controls. Balon and col-
leagues (1989) infused with lactate 45 subjects who had no PD or any other men-
tal illness. Ten subjects experienced panic attacks in response to lactate infusion.
Eight of 10 subjects with lactate-induced panic attacks and 26 of 35 without panic
attacks were interviewed about family history. A higher prevalence of anxiety
disorders was found among first-degree relatives of subjects with lactate-induced
panic attacks than among relatives of subjects who did not panic. It was suggested
that individuals with a family history of anxiety disorders might be vulnerable to
lactate-induced panic attacks (Balon et al., 1989).
To test the hypersensitivity to COT inhalation as a possible trait marker for
PD, Coryell (1997) recruited two high-risk groups for PD and affective disorder,
respectively, and a low-risk control group. Eleven subjects at high-risk for PD
had at least one first-degree relative who had been treated for PD. Those subjects
were compared with a group of 13 individuals who were at high risk for affective
disorder. The low-risk controls had no first-degree relatives with either affective
disorder or PD. All of the subjects took the COT challenge. Five of the subjects
at high risk for PD, but none of the controls or any of the individuals at high risk
for affective disorder, experienced a panic attack following the CCh challenge.
These results confirm an association between hypersensitivity to excessive CO2
and familial vulnerability to PD (Coryell, 1997).
Perna et al. (1995) tested the sensitivity to 35% CO2 in healthy first-degree
relatives of PD patients. The procedure they used was similar to ours. Eighty-
four patients with PD, 23 first-degree relatives of PD patients, and 44 healthy
controls with no family history of PD inhaled 35% CO2 / 65% (X Fifty-one
percent of the PD patients compared to 22% of the first-degree relatives and 2% of
the healthy controls experienced CC^-provoked panic attacks. They found that the
first-degree relatives reacted significantly more strongly to the 35% CO2 challenge
than healthy controls and significantly less strongly than the PD patients (Perna
etal., 1995).
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One difference with the above-mentioned studies of Coryell and Perna et al. is that
our sample is matched for age and gender to exclude possible influences of it on
the results. Perna, Coryell and we all found that first-degree relatives have more
CC>2-induced panic attacks than controls — 22%, 45% and 44% respectively. But
a striking difference in our study and the two earlier studies is in the proportion
of controls with COi-induced panic attacks: 2% (Perna), 0% (Coryell) and 24%.
Both above-mentioned studies used different criteria in defining panic attacks, us-
ing the PSL III—R. To be as conservative as possible we chose to take a very low
threshold of assessing panic attacks, using the VAS-A and PSL III—R. This might
explain the high score of panic attacks in control subjects. It is suggested that the
VAS-A the easiest way is to measure effects of the CO2 challenge and that the
rating of panic symptoms, assessed by the PSLIII-R. does not have any discrimi-
native value (Verbürg et al., 1998). Differences in the assessments and thresholds
used to score panic attacks may contribute to the differences in the amount of panic
attacks. It is a common problem in defining exactly how to assess panic attacks,
which makes comparing studies difficult (Pols, Verbürg, & Griez, 1994).
Finally, Perna et al. (1996) also investigated the relationship between hyper-
sensitivity to COT and familial-genetic risk for PD in patients with PD. Twohun-
dred patients with PD were challenged with 35% CCK Of the PD patients, 157
(77%) were 35% COi-sensitive. The morbidity risk for PD was calculated for
families of the patients with PD. The morbidity risk was significantly higher for
the subjects who were hypersensitive to 35% COi than for those with normal sen-
sitivity to CO2. Subjects who were hypersensitive to 35% CO2 seemed to have
a clear familial-genetic vulnerability to PD (Perna et al., 1996). The same group
conducted a twin study and found a significantly higher concordance rate for 35%
COi-induced panic attacks among monozygotic than dizygotic twins. The au-
thors suggest a role of genetic factors in sensitivity to CO2 inhalation (Bellodi
et al., 1998). CO2 hypersensitivity may be due to a particular genetic dysfunction
and can play a role in genetic studies as a possible phenotypical marker of panic
vulnerability.
All of the above-mentioned studies indicate an association between panic vul-
nerability triggered by lactate or COT and a constitutional predisposition to PD
that runs in families. Using experimental panic provocation in the largest group of
first-degree PD relatives ever, our study confirms the above results.
Two different explanations for the reactivity to the COi challenge have been
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proposed. Some authors suggest a key role of yet undefined biological abnor-
malities. For example, a hypersensitive reaction to CO2 fits the false suffocation
alarm hypothesis developed by Klein (1993). Klein hypothesizes that COi hyper-
sensitivity is due to a deranged suffocation alarm monitor. Since it is argued that
subjects with panic attacks have an oversensitive suffocation detector, first-degree
PD relatives may have such a disrupted detector too, which may explain their hy-
persensitive reaction to COT. However, respiratory indices of a false suffocation
monitor were not assessed in the present study. In line with the false suffocation
theory is the study of Horwath et al. (1997). If smothering symptoms are a marker
for a hypersensitive suffocation detector, and if this hypersensitivity is familial,
then first-degree relatives of PD patients with smothering symptoms would have
higher rates of panic than first-degree relatives of PD patients without smothering.
This was confirmed (Horwath et al., 1997).
Others explain the specific reactivity to CO2 challenges on the basis of psycho-
logical factors. CO2-induced panic is supposed to be a consequence of cognitive
misinterpretation of the induced bodily symptoms. Subjects undergoing a COi
challenge perceive these bodily sensations as much more dangerous than they re-
ally are (Clark, 1986; Sanderson, Rapee, & Barlow, 1989). Our data can not ex-
clude a possible role of cognitive factors, since specific cognitive patterns may run
in families. Interestingly, a recent study by Stein and colleagues (1999) investi-
gated the role of a psychological factor that predisposes one to panic. The authors
examined the heritability of anxiety sensitivity in a group of 179 monozygotic and
158 dizygotic twin pairs. This study suggests that anxiety sensitivity has a strong
heriditary component (Stein et al., 1999).
In sum, the present findings indicate that being a member of a family with a PD
patient is, in itself, an important factor in CO2 hypersensitivity, even for subjects
who have never experienced a panic attack. This suggests that first-degree rela-
tives of PD patients have an apparent vulnerability to CO2 which, in turn strongly
suggests that CO2 hypersensitivity may be a marker of a familial vulnerability to
PD. The nature of this vulnerability, however, remains unclear. It is known that
PD runs in families and anxiety sensitivity has been proposed as a risk factor for
the development of PD. It is be possible that first-degree relatives of PD patients
have an increased anxiety sensitivity that may cognitively mediate the response
during the CO2 challenge. Further work is needed to characterize the potential
role of anxiety sensitivity as a vulnerability factor in PD. An evaluation of anxi-
27
Chapter 2
ety sensitivity in first-degree relatives of PD patients may more fully elucidate the
relationship between CO2 reactivity and PD.
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Does age or sex influence anxiety sensitivity?
Objective: We investigated the role of sex and age on anxiety sensitivity in patients
with panic disorder.
Method: One hundred and sixteen patients with panic disorder filled out the Anx-
iety Sensitivity Index (ASI). Analyses of age and sex were performed on the ASI
scores of the patients.
Results: ASI scores did not differ on the basis of sex. Nor was any age-related
difference in ASI scores found. Moreover, age did not differ with sex, although
there was a tendency for younger women to have higher ASI scores than men.
Conclusions: We did not find a clear relation between sex and anxiety sensitivity.
We suggest that anxiety sensitivity was similar across age groups. The influence
of sex or age on ASI calls for further documentation.
van Beek, N., Schruers, K. & Griez, E. (submitted). Does age or sex influence anxiety sensitivity?
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Introduction
The construct of trait anxiety refers to individual differences in anxiety proneness.
However, people vary not only in how prone they are to experience anxiety symp-
toms, but also in their fear of those symptoms (McNally, 1999). Some individuals
tend to regard the sudden pounding of their heart as life-threatening, whereas oth-
ers experience this as merely unpleasant. The construct of anxiety sensitivity (AS)
deals with these individual differences in the fear of anxiety (Reiss & McNally,
1985). More specifically, AS refers to fears of anxiety-related sensations based
on beliefs that these sensations have harmful consequences (Reiss & McNally,
1985). The Anxiety Sensitivity Index (ASI; Reiss et al., 1986; Peterson & Reiss,
1992) has been the most commonly used instrument to measure AS. The ASI is
a questionnaire assessing how much the subject is concerned when experiencing
symptoms commonly associated with anxiety, such as fear of physical sensations,
fear of loss of cognitive control, and fear of publicly observable symptoms (Taylor,
Koch, Woody, & McLean, 1996; Zinbarg, Barlow, & Brown, 1997).
A small number of studies have assessed sex differences in ASI scores. One
report mentions higher ASI scores for female students in a large sample of 818
university students (Stewart, Taylor, & Baker, 1997). However, as stressed by the
author, in this particular population, social desirability response bias may have
played a role. Male students tend to underreport their actual fears, which explains
their lower scores relative to female students. The same reasoning may apply to a
recent investigation reporting higher scores in female native American Indian and
Alaskan college students (Zvolensky, McNeil, Porter. & Stewart, 2001). One study
addressed a clinical population. This investigation assessed AS in 61 female and
27 male panic disorder (PD) patients. There was a significant difference between
the sexes, with higher ASI values in female patients (Schmidt & Koselka, 2000).
To our knowledge, this is the only report addressing sex differences on AS in a
population with pathological anxiety.
There are factors other than sex that may influence ASI scores. One of them
is age. Currently, there is little or no evidence for a possible effect of age on
ASI scores. Previous studies with the ASI either used subjects who did not differ
in age (Ball, Otto, Pollack, Uccello, & Rosenbaum, 1995) or subjects matched
for this variable (Asmundson & Stein, 1994). It is, however, conceivable that a
50-year-old may be more worried by palpitations than a 20-year-old. The only
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study we are aware of measured AS in a group with a limited age range. The
sample was divided into two groups, one that included subjects aged 40 to 60 years
and one aged 60 to 93 years. Contrary to what might be expected, the younger
than 60 group had significantly higher ASI scores than those over 60 (Owens,
Hadjistavropoulos, & Asmundson, 2000).
There is support for high AS as a risk factor for the development of anxiety
disorders, PD in particular (Reiss, 1991), and the ASI is widely used in anxiety
research. In view of the above, additional investigation into the role of age and sex
on AS seemed warranted. We sought to confirm the findings that women report
higher ASI scores than men in a broader sample of participants with a clinical
diagnosis of PD. This sample was also an opportunity to further document the
influence of age on AS.
Method
Participants
One hundred and sixteen PD(A) patients participated in the present study. All
participants were 18 years and over (range 18-66, mean = 39.9, SD = 11.5). The
sample consisted of 49 male (42.2%) and 67 female (57.8%) participants. Age was
normally distributed. To divide the total sample into two age groups, we conducted
a median split, resulting in a 'younger' group (aged 18 to 40) and an 'older' group
(aged 41 to 66).
Assessment
All participants were given the Mini International Neuropsychiatric Interview
(MINI) to confirm their diagnosis, and they filled out the ASI. The MINI is a short,
structured diagnostic interview for DSM-IV psychiatric disorders, developed by
psychiatrists and clinicians in the U.S. and Europe. The MINI has been found to
be a reliable and valid instrument (Lecrubier et al., 1997; Sheehan et al., 1997).
The ASI is a 16-item self-report questionnaire to assess fear of anxiety-related
symptoms on a 5-point Likert-type scale (0 = no anxiety to 4 = maximum anxi-
ety) (Reiss et al., 1986). Each item assesses concern about the possible negative
consequences of anxiety symptoms (Schmidt et al., 1997). An individual's AS
score is the sum of the scores on the 16 items. The results of a factor analysis
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of the ASI (Zinbarg et al., 1997) imply good internal reliability for the scale as a
whole. Mailer and Reiss (1992) reported a test-retest reliability of 0.71 for college
students over 3 years (Mailer & Reiss, 1992). Schmidt (1997) reported a 5-week
test-retest correlation of 0.65, although participants had undergone a highly stress-
ful military training in between (Schmidt et al., 1997). These results suggest that
AS is a stable construct and that the ASI is a reliable measure of AS.
Data analyses
A Pearson correlation was calculated between age and ASI score. A 2 (age:
younger or older) x 2 (sex: male or female) ANOVA was performed on the ASI
scores. All independent variables were between subject variables.
Results
45
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Total group Male subjects Female subjects
Figure 3.1 Mean ASI scores (+SD) for the entire sample and per sex
Correlational analyses
The mean of ASI scores was 25.7 (SD = 11.5) for the total sample (Figure 3.1) and
the mean age was 39.9 (SD = 11.5). No significant correlation was found between
age and ASI (r =-0.12).
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Figure 3.2 Mean ASI scores (+SD) for men and women in function
of age groups
Analysis of variances
The mean ASI score of the male participants was 23.5 (SD = 11.3) and it was 27.3
(SD = 11.3) for the female participants (Figure 3.2). fto significant main effect
was found for sex on ASI (F(l,l 12) = 3.2, p = 0.076). No significant difference
was found between the younger group (mean ASI 26.5, SD = 11.3) and the older
group (mean ASI 24.4, SD = 11.5) (F(l,l 12) = 0.9, p = 0.33).
Furthermore, age did not significantly interact with sex (F(l,l 12) = 3.2, p =
0.076) (Figure 3.2). To further explore the interaction effect, a post-hoc Tukey
HSD for unequal N was performed. This did not reveal any significant differences,
although younger women tended to score higher on the ASI than younger men.
Discussion
In the present study we found no influence of sex or age on anxiety sensitivity
in patients with panic disorder. Contrary to both previously mentioned studies of
Stewart and Zvolensky, in which female participants scored significantly higher
than male participants on the ASI (Stewart et al., 1997; Zvolensky et al., 2001),
we found no significant effect of sex on AS. It should, however, be borne in mind
that both of those studies addressed a specific population of college students; in
Zvolensky's case, the population was even more specific, including native Alaskan
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and American Indian students. The possible cultural bias in this subpopulation.
male subjects possibly tending to underreport their fears, may help to explain the
difference between Stewart's and Zvolensky's studies, on the one hand, and the
present study, on the other. Yet, still another factor may play a role. Both previous
studies investigated a normal healthy population. We addressed patients referred
for treatment to a specialized clinic. The mean ASI score in our sample was 25.7,
almost twice that found in Stewart's participants. Our patients suffered from se-
vere anxiety associated with physical symptoms that are typical for PD. They may
have been more prone to report their fears as such than individuals with a less
pronounced, subclinical symptomatology, regardless of whether they were male
or female. Alternatively, AS may increase after people start experiencing panic
attacks and certainly after they develop PD with its prominent physical symptoms.
It may be that pre-existing sex differences in AS in nonclinical samples are lev-
elled out when developing a PD. It is possible that a risk factor, i.e., AS, may act
differently as a premorbid risk than as a pathoplastic risk, that is, after the disorder
is manifest. On the other hand, one paper reported significant sex differences on
the ASI between 61 female and 27 male PD patients (Schmidt & Koselka. 2000).
Although, at first sight, this finding seems to be at odds with our results, a closer
examination of our data show that sex tended to interact with age. In line with
the above-mentioned study in patients (Schmidt & Koselka, 2000), we found that
younger women tended to be more anxiety sensitive than younger men.
In the present study we found no relation between age and ASI scores. Ac-
cording to our findings, older persons are no more concerned than young people
about possible harmful consequences of discomfort related to anxiety. In other
words, the higher the age does not necessarily mean the higher the AS. Interest-
ingly, others have found that not only ASI as a whole, but also its internal structure
seem to be similar across age groups. When looking at the structure of AS in older
adults (aged 65 to 97 years, with a mean of 75) compared to younger people, factor
analysis revealed that the ASI construct had a highly similar structure in both age
groups (Mohlman & Zinbarg, 2000). Unfortunately, no absolute ASI scores were
mentioned in this study. Another study, also examining an older population, did
report ASI scores. They found that people under 60 scored higher on the ASI than
those over 60 (Owens et al.. 2000).
In sum. in spite of our sample, which was larger than that in the previously
mentioned study with patients (Schmidt & Koselka, 2000), we failed to rind clear-
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cut differences between AS and sex in this particular sample of PD patients. More-
over, the present study suggests that AS is similar across age groups. Therefore,
given the previous findings, further studies on the influence of sex or age on ASI
appear to be warranted.
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Anxiety sensitivity in first-degree relatives of
patients with panic disorder
Anxiety sensitivity has been proposed as a risk factor for the development of panic
disorder. Strong familial-genetic influences in panic disorder have been reported.
Anxiety sensitivity may be familial too. The current study therefore examined
whether first-degree relatives of panic disorder patients are more anxiety sensitive
than normals. Twenty-three first-degree relatives of panic disorder patients, 38
panic disorder patients and 30 normals were given the Anxiety Sensitive Index
and the Body Sensations Questionnaire. It was found that the first-degree relatives
were, indeed, more anxiety sensitive than the normals, but less so than the panic
disorder patients, suggesting that anxiety sensitivity runs in families.
van Beek, N., & Griez, E. (2003). Anxiety sensitivity in first-degree relatives of patients with panic
disorder. ße/iavj'onr /tesea/r/i ant/ 77iera/7)>, 47(S^, 949-957.
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asthma or bronchitis, and had never experienced a panic attack according to the
DSM-IV. All PD patients were diagnosed according to the DSM-IV criteria by
two experienced psychiatrists.
Procedure
Self-administered questionnaires that the subjects filled out included the ASI (Reiss
et al., 1986) and BSQ 1 and 2 (Chambless et al., 1984). The ASI is a 16-item
self-report questionnaire to assess fear of anxiety-related symptoms on a 5-point
Likert-type scale (0 = no anxiety to 4 = maximum anxiety) (Reiss et al., 1986).
Each item assesses concern about the possible negative consequences of anxiety
symptoms (Schmidt et al., 1997). An individual's AS score is the sum of the scores
on the 16 items. The BSQ is a 17-item questionnaire that measures fear of bodily
symptoms that are common to autonomic arousal on a 5-point Likert-type scale
(1 = not at all afraid to 5 = very much afraid). Two versions, each containing 17
items, were used: the BSQ1 measures how afraid people are of bodily feelings and
BSQ2 measures how often these feelings occur (Chambless et al., 1984).
Data analysis
To determine whether the first-degree relatives were more anxiety sensitive, as as-
sessed by the ASI, than the normals, a non-parametric analysis (Kruskal-Wallis)
was applied, because the within-group variances are unequal. The same analysis
was used for the BSQ. Additional Student t-tests were used to determine group dif-
ferences between PD patients and normals, between PD patients and first-degree
relatives, and between first-degree relatives and normals on the ASI and BSQ
scores. Welch t-tests were used instead of Student t-tests if the variances in the
two groups were significantly different.
Results
The mean score on the ASI was 26.2 (SD = 10.2) for the PD patients, 9.2 (SD =
7.3) for the first-degree relatives, and 5.2 (SD = 3.0) for the normals (Fig. 4.1).
The mean score on the BSQ1 was 46.3 (SD = 13.2), 27.9 (SD = 8.0), 24.1 (SD =
6.0) for the PD patients, the first-degree relatives, and normals, respectively (Fig.
4.2). On the BSQ2, the scores were 45.0 (SD = 10.7) for the PD patients, 27.0
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Figure 4.1 ASI scores (+SD) of panic disorder patients,
first-degree relatives and normals
(SD = 7.4) for the first-degree relatives, and 26.3 (SD = 5.2) for the normals. No
significant difference was found in gender between the three groups (#~ = 2.8, df
= 2, p = NS), but age significantly differed between the three groups (H = 27.7, df
= 2, p < 0.001).
Significant differences were found for ASI scores (H = 58.4, df = 2, p < 0.001),
BSQ1 scores (H = 50.5, df = 2, p < 0.001), and BSQ2 scores (H = 48.1, df = 2,
p < 0.001). t-tests indicated that the ASI and BSQ1 and BSQ2 were significantly
different between normals and PD patients, respectively (Welch t(45) = -12.1, p
< 0.0001; Welch t(54) = -9.2, p < 0.0001; Welch t(56) = -9.5. p < 0.0001) and
between first-degree relatives and PD patients (Student t(59) = -7.0, p < 0.0001;
Welch t(59) = -6.8, p < 0.0001; Welch t(58) = -7.7, p < 0.0001). The scores on the
ASI were significantly different between normals and first-degree relatives (Welch
t(28) = 2.5, p < 0.01), but those on the BSQ1 (Student t(51) = 2.0, p = NS) and
BSQ2 (Student t(51) = 0.5. p = NS) were not.
Discussion
As assessed by the ASI and in line with our hypothesis, we found that first-degree
relatives of PD patients were more anxiety sensitive than normals. In contrast, PD
relatives had no increased ratings on the BSQ.
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Figure 4.2 BSQ1 scores (+SD) of panic disorder patients,
first-degree relatives and normals
While both questionnaires clearly yield augmented scores in the patient' popula-
tion, the discrepancy in outcome between the ASI and the BSQ in the group of
first-degree relatives is noteworthy. It may indicate that the ASI is a more sen-
sitive measure than the BSQ. Possibly, a larger sample is needed to find group
differences on the BSQ. Alternatively, the present results may support the view
that the ASI and the BSQ do not measure exactly the same concept. The BSQ
was introduced on the premise that physical symptoms of panic attacks may them-
selves become conditioned signals of fear (Goldstein & Chambless, 1978). On
the contrary, the ASI was designed to assess the fear of becoming anxious, i.e., a
cognitive pattern that is assumed to favor the development of panic attacks (Reiss
& McNally, 1985). It was subsequently stressed that the construct assessed by the
ASI may comprise both the cognitive pattern predisposing to, and the conditioned
fear resulting from, the panic experience (Reiss, 1987). In fact, factor analyses
have shown the ASI to contain several dimensions (Stewart et al., 1997; Taylor,
1996). Although one investigation in agoraphobics found a good correlation be-
tween the ASI and the BSQ (McNally & Lorenz, 1987), this correlation was rather
poor in another study (Asmundson et al., 1996). Thus, there are several arguments
that support the ASI's potential to encompass both a cognitive risk that predisposes
to panic and the fears that are the result of panic attacks, while the BSQ assesses
only the latter dimension. Logically, both those having the risk factor only (the
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PD patients' relatives) and those having the risk as well as the consequences (the
PD patients) will be discriminated from normals by the ASI, while the BSQ will
discriminate only those suffering from the psychological consequence. That is ex-
actly the pattern we observe in the present study. Assuming that the ASI score is
a composite construct, reflecting both antecedents and consequences of panic, it
seems only logical that, of the three groups, the PD patients had the highest scores,
while much lower values were found in their first-degree relatives.
As for our main hypothesis, we had put forward that high AS may run in first-
degree relatives of PD subjects. The results are consistent with our hypothesis.
When the concept of AS was first proposed, the authors posited that genetic fac-
tors might be involved (Reiss & McNally, 1985). In fact, until recently, little was
known about the origin of the complex construct represented by AS. The earlier
mentioned study by Stein et al. (1999) revealed that there is a definite hereditary
component in the transmission of AS, the correlation of the total AS score, for in-
stance, being 0.47 between monozygotic twins and 0.17 between dizygotic twins.
In particular, factor 1 of the ASI, related to the beliefs about harmfulness of phys-
ical sensations, seems to contain a strong genetic component: additive genetic
factors accounted for 35% for factor 1 and for 45% erf the total variance on the
ASI score. Moreover, Stein's study strongly suggests that scores in the high range
of the ASI, typically found in PD patients, and scores in the subclinical range,
encountered in nonsymptomatic subjects, share the same common genetic basis
(Steinetal., 1999).
In the past, investigators have hypothesized that not only specific genetic fac-
tors, but also specific learning experiences may influence specific factors of AS,
e.g. how much one learns about the danger of cardiac symptoms may determine
one's fear of those sensations (Taylor & Cox, 1998). In particular, Ehlers (1993)
examined the relationship between specific childhood learning experiences and the
degree of fear of anxiety-related symptoms in panickers. She suggested signifi-
cant associations between levels of fear of anxiety-related symptoms in adulthood
and anxiety-specific learning experiences in childhood and adolescence (Ehlers,
1993). Contradicting Ehlers findings. Watt, Stewart, and Cox (1998) found that
the learning experiences reported by high anxiety sensitive individuals (although
not clinically ill) were not specifically related to anxiety symptoms, but rather in-
volved parental reinforcement of sick role behavior in general. It was suggested
that it is learning to catastrophize about the occurrence of bodily discomfort in
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general, rather than anxiety-related symptoms in particular, that leads to higher
than normal levels of AS (Watt, Stewart, & Cox, 1998). Thus, the exact function
of distinctive patterns of environmental influences on specific AS factors remains
unclear.
Besides the influences mentioned above, gender differences may play a role in
AS. Some studies found females to be more anxiety sensitive than males (Schmidt
& Koselka, 2000; Stewart et al., 1997; Zvolensky et al., 2001). We had a slightly
higher proportion of females than males in the first-degree relatives group. How-
ever, the gender difference both across and within the three groups failed to reach
statistical significance. Admittedly, our groups significantly differed in age. Yet,
there was no reason to match the subjects for age. Age does not seem to modulate
ASI scores (Mohlman & Zinbarg, 2000). As far as age and gender are concerned,
it is worth mentioning that a recent study by our group failed to find a definite
global effect of age on ASI in a clinical sample of 116 PD patients (Van Beek,
Schruers, & Griez, submitted for publication).
Increased AS is obviously not a sufficient condition to develop a PD. AS may
be part of a large complex etiological picture where a variety of psychological
and (neuro)biological factors must be taken into account. No one in our sample
of first-degree relatives had ever developed a PD, because we explicitly excluded
first-degree relatives with a lifetime history of PD. Moreover, most of the first-
degree relatives studied will probably never develop a PD, considering that the
mean age of our sample is 50.0 yr, well above the peak age of onset for PD i.e.
25 yr (DSM-IV; American Psychiatric Association, 1994). It may be argued that
only those with an ASI score in the high range are at risk for PD, while the scores
of our first-degree relatives are only moderately increased, although significantly
higher than those of normals. However, Donnell and McNally (1990) found that
two-thirds of a group of high anxiety sensitive subjects had never experienced a
spontaneous panic attack (Donnell & McNally, 1990). More prospective studies
are needed to test to what extent AS is a predictor of the development of PD.
In previous studies, both we and others have shown that first-degree relatives
of PD patients have an enhanced sensitivity to CO2 (Coryell, 1997; Perna et al.,
1995, 1996; Van Beek & Griez, 2000). Enhanced CO2 sensitivity is known to af-
fect individuals suffering from panic attacks and/or situational phobias (Battaglia
& Perna, 1995; Griez & Schruers, 1998; Verbürg et al., 1998). in sharp contrast
to individuals with other anxiety disorders or to normals. Therefore, CO2 vul-
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nerability may identify subjects with a constitutional predisposition to developing
panic. The present results show that first-degree relatives of PD subjects also have
an increased AS. It may be tempting to make a link between high CO? vulner-
ability and increased AS. Some authors have posited that high AS may explain
high vulnerability to biological challenges (Forsyth, Palav, & Duff, 1999). Yet,
in a well-controlled study including both normals and PD patients, cognitive ma-
nipulation failed to influence the results of a CO2 challenge (Welkowitz, Papp,
Martinez, Browne, & Gorman, 1999). Moreover, analysis of 35% CO2 challenges
in PD subjects recently showed that CO2-elicited anxiety was not significantly
predicted by ASI scores, although ASI scores predicted the symptomatological re-
action to CO2 (Perna, personal communication). Furthermore, in another study the
total ASI scores did not correlate with post-COi scores (Koszycki & Bradwejn,
2001). On the other hand, a small study in PD did find a correlation between ASI
and the response to CO2 (Shipherd, Beck, & Ohtake, 2001).
Assuming that COi vulnerability is not merely a consequence of high AS, it
is conceivable that both CO2 vulnerability and high AS are the expression of a
third factor that runs in families and predisposes to panic. Alternatively, AS and
CO2 vulnerability may identify two independent factors, that operate separately in
two different subtypes of PD. Recent findings with the 35% CO2 challenge have
supported the idea that CO2 vulnerability may vary across subtypes of PD (Biber
& Alkin, 1999). It remains to be established whether the same applies to AS and,
if so, whether the same subtypes are defined by both high COi susceptibility and
enhanced AS.
To summarize, we have found that healthy first-degree relatives are signifi-
cantly more anxiety sensitive than normals, suggesting that high AS runs in fam-
ilies. This finding may imply that first-degree relatives have a certain cognitive
attitude that may contribute to the development of PD. However, future research is
required to clarify the exact role of AS as a predictor of PD.
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Anxiety sensitivity in children of panic
disorder patients
Background: Anxiety sensitivity, which refers to the tendency to interpret anxiety-
related bodily sensations as having potentially harmful somatic, psychological or
social consequences, has been proposed as a vulnerability factor for the develop-
ment of panic disorder. The current study examined the anxiety sensitivity levels
in children of parents with panic disorder.
Methods: Children of panic disorder patients (n = 68) and children of healthy
parents (n = 68) filled out the Childhood Anxiety Sensitivity Index, while parents
completed the Anxiety Sensitivity Index.
Results: Children of parents with panic disorder did not display higher levels of
anxiety sensitivity than children of healthy parents. Furthermore, no association
between anxiety sensitivity levels of parents with panic disorder and their children
was found.
Conclusions: Anxiety sensitivity is not clearly manifest in children of parents with
panic disorder and might be a developing vulnerability factor that may increase
towards late adolescence or early adulthood.
van Beek, N., Perna, G., Schmers, K., Muris, P., Griez, E. (submitted). Anxiety sensitivity in
children of panic disorder patients.
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Introduction
Anxiety sensitivity (AS) refers to the extent to which an individual fears anxiety-
related sensations based on the expectation that such sensations can have harmful
consequences (Reiss, 1997; Reiss & McNally, 1985). Research findings show
that adults with high AS are more likely to develop a panic disorder (PD) than
those with low AS (Mailer & Reiss, 1992; Reiss, 1991). Conversely, PD subjects
have been found to score higher on AS than healthy individuals, and in general
than people with other anxiety disorders (Taylor et al., 1992). It has therefore
been suggested that AS predisposes to the development of anxiety disorders, in
particular PD.
Increased AS has been documented in adult first-degree relatives of PD pa-
tients, who have never experienced a panic attack (Van Beek & Griez, 2003). This
suggests that high AS may run in PD families. Strikingly, a twin study indicated
that AS may have a strong hereditary component (Stein et al., 1999).
Considering the familial-genetic influences involved in the development of PD
(Coryell, 1997; Crowe et al., 1983; Goldstein et al., 1997; Torgersen, 1983), the
above finding of high AS in PD families, and the possible heritability of AS, one
would expect to find increased AS in children of PD patients. If AS operates in a
similar way in children as it does in adults (i.e., as a risk factor for the development
of panic attacks), high AS in children may be of practical relevance for primary
prevention. Thus, research on AS in children may be warranted for a better under-
standing of the development of PD. Despite the broad interest in AS in adults, AS
has been relatively understudied in children.
AS can be measured with a specially developed questionnaire for children,
the Childhood AS Index (CASI) (Silverman, Fleisig, Rabian, & Peterson, 1991),
which is a modified version of the adult AS Index (ASI; Reiss et al.. 1986). The
CASI has good internal consistency and test-retest reliability (Silverman et al.,
1991; Van Widenfelt, Siebelink, Goedhart, & Treffers, 2002). In a sample of 280
children, aged 6 to 17 years, it was found that the CASI showed incremental valid-
ity, meaning that the CASI predicted a significant amount of additional variance in
fear beyond that predicted by trait anxiety (Weems, Hammond-Laurence, Silver-
man, & Ginsburg, 1998).
In most studies, the CASI differentiated children with anxiety disorders from
normal control subjects (Rabian, Peterson, Richters, & Jensen, 1993; Vasey, Dalei-
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den, Williams, & Brown, 1995). However. AS may not differentiate among a
clinical population, as children with an anxiety disorder were not more anxiety
sensitive than children with an externalizing disorder (i.e., ADHD or conduct dis-
order). PD as such was, however, not represented in this particular study (Rabian
et al., 1993). Another investigation did take PD into account, and showed that
children with PD scored significantly higher on the CASI than those with other
anxiety disorders (Kearney, Albano, Eisen, Allan, & Barlow, 1997). Furthermore,
AS in adolescents was significantly related to panic symptoms (Lau, Calamari, &
Waraczynski, 1996; Muris et al., 2001). Adolescents with a lot of panic attack
symptomatology reported significantly higher levels of AS than the non-panickers
(Lauetal., 1996).
Although on a cross sectional basis the CASI may differentiate between anx-
ious children and others, the prediction of panic attacks by high CASI scores in
follow-up studies has been hardly examined. Nevertheless, there is some evidence
demonstrating that high AS predicted panic attacks assessed over a 4-year period
in high school students (Hayward, Killen, Kraemer, & Taylor, 2000; Weems, Hay-
ward, Killen, & Taylor, 2002). However, in another study, earlier levels of AS did
not predict the occurrence of panic symptoms six months later after controlling for
initial levels of panic (Ginsburg & Drake, 2002). Thus, there are several issues
where available findings are not consistent. In the present study, we investigated
whether children of PD patients display higher levels of AS on the CASI than chil-
dren of healthy controls. Because parents may pass on AS, either via a genetic
pathway or via observational learning, we additionally examined, in a subsample
of our participants, whether there is a correlation between the parents' and their
offspring's AS.
Method
Participants
One-hundred-thirty-six children, aged 6-17 years (mean age = 11.9 years, SD =
2.9) participated in the present study. Sixty-four (47.1%) children were recruited
in the Netherlands (Maastricht) and 72 (52.9%) in Italy (Milan). The total group
consisted of 75 boys (55.1%) and 61 girls (44.9%).
Sixty-eight children of PD patients (PD child group) (mean age = 11.7 years,
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SD = 3.2, 35 boys (51.5%), 33 girls (48.5%)) were recruited among patients treated
at clinics in Maastricht (n = 31) or Milan (n = 37). Sixty-eight children of healthy
subjects without a family history positive for PD (control child group) (mean age
= 12.2 years, SD = 2.6, 40 boys (58.8%), 28 girls (41.2%)) were recruited among
the hospital staff and among friends of the members of the research teams. Thirty-
three control children participated in Maastricht and 35 in Milan.
Data of AS in parents were collected in Maastricht. Sixteen parents with PD
(mean age = 42.7 years, SD = 3.8, 4 males (25%), 12 females (75%)) and 33
healthy parents of the control group (mean age = 41.8 years, SD = 4.2, 6 males
(18.2%), 27 females (81.8%)) filled out the Anxiety Sensitivity Index (ASI) (Reiss
et al., 1986). We attempted to match the proportion of males and females between
the PD parents and the control parents.
Procedure
The study was approved by the local medical ethics committee. All parents with
PD in Maastricht and Milan were diagnosed according to DSM-IV criteria by
experienced psychiatrists using the Mini International Neuropsychiatric Interview
(MINI) (Sheehan et al., 1997). The MINI is a short structured diagnostic interview
measuring psychiatric disorders on axis 1 of the DSM-IV. One Dutch PD parent
had a comorbid dysthymia and one a comorbid major depressive disorder. Parents
of the control children in Maastricht and Milan were also interviewed with the
MINI (Sheehan et al., 1997) to exclude anxiety disorders on axis I according to
DSM-IV. These parents were indeed free of psychiatric disorders.
All children filled out the CASI (Silverman et al., 1991). Complementary in-
formation on the children's emotional status was available in Maastricht from the
Screen for Child Anxiety Related Emotional Disorders (SCARED: Birmaheret al.,
1997; Muris, Merckelbach, Schmidt, & Mayer, 1999). In Milan the children were
interviewed by a child psychiatrist using the Diagnostic Interview for Children and
Adolescents (Herjanic & Campbell, 1977). Additional to the screening, the parents
in both centers were interviewed about their children with a specially developed
checklist concerning the exclusion criteria. Exclusion criteria for all children were
important medical diseases (important cardiovascular diseases, respiratory disor-
ders, epilepsy, attention deficit hyperactivity disorder Silverman et al., 1991), sig-
nificant traumatic experiences, evidences of mental retardation, significant school
50
Anxiety sensitivity in children
difficulties. From this information, it appeared that children in both centers did not
suffer from severe health or mental problems, except for one child in the PD group
in Maastricht who had diabetes, but scored within the range of this group on the
CASI.
Assessment
As mentioned previously, the CASI (Silverman et al., 1991) is a specially devel-
oped instrument for assessing AS in the youth (aged 6-17 years). The CASI is an
18-item self-rating scale that requires children to rate their fear of anxiety-related
sensations, using a 3-point scale (none = 1, some = 2, a lot = 3). CASI total scores
range from 18 to 54. The CASI assesses fears of the same types of anxiety-related
sensations as its adult counterpart, the ASI (Reiss et al., 1986).
The ASI (Reiss et al., 1986) is a 16-item self-report questionnaire to assess
fear of anxiety-related symptoms on a 5-point Likert-type scale (0 = no anxiety
to 4 = maximum anxiety). Each item assesses concern about the possible negative
consequences of anxiety symptoms. An individual's AS score is the sum of the
scores on the 16 items.
< " *
Data analyses
Gender and age differences between the PD child group and the control child group
were tested by means of Chi-square test and Student t—test, respectively. Differ-
ences in CASI scores between the PD child group and control child group were
analyzed by means of a Student t-test (two-tailed). The relation between AS of
the parents and their children was examined by computing a Pearson correlation.
To examine if PD parents were more anxiety sensitive than the healthy parents a
Welch t-test was applied (two-tailed).
Results
The two groups of children did not differ in gender or age. The mean score on
the CASI was 28.2 (SD = 5.3) for the PD child group and 27.8 (SD = 5.5) for the
control child group. This difference was not statistically significant.
In the subsample where parents also were assessed, the parents with PD had
a mean ASI score of 15.9 (SD = 9.7), whereas their offspring scored 26.9 (SD =
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5.6) on the CASI. The healthy parents scored on average 5.8 (SD = 3.9) on the
ASI and their children scored 25.3 (SD = 4.7) on the CASI. Note that parents with
PD were significantly more anxiety sensitive than healthy parents (t( 17) = 4.0; p <
0.001), whereas no significant differences emerged in their children. Correlations
between AS scores of children (CASI) and their parents (ASI) were .04 in PD
families, and .15 in healthy families. Thus, no statistically significant association
between parents' and children's level of AS was found.
Discussion
As expected, parents with PD displayed higher levels of AS than healthy parents.
However, the results of the present study also demonstrate that children of PD par-
ents are not more anxiety sensitive than children of healthy parents. Accordingly,
no link, was found between AS scores of PD parents and their offspring.
It was hypothesized that parents with PD would predispose their children to
high AS. However, PD parents do not seem to pass on high AS to their children.
Since completing our study, we learned that Mannuzza and colleagues (2002) re-
cently conducted a study on the same topic. These researchers compared CASI
scores of children who had parents with PD. other anxiety and/or mood disorders,
and no psychiatric disorder, and also found no differences among these groups
(Mannuzza et al., 2002). It is also important to note, that the mean CASI scores of
children with PD parents in the present study (28.2) and in Mannuzza et al.'s study
(27.2) were highly comparable to the mean scores of normal children (27.8 in our
study versus 27.9 in Manuzza et al.'s study). Thus, the above results appear to be
quite robust and seem to indicate that high AS in PD parents does not necessarily
predispose their offspring to be highly anxiety sensitive. Yet, results of our previ-
ous study show that adult first-degree relatives of PD patients displayed increased
AS levels compared to controls (Van Beek & Griez, 2003).
The failure to detect a difference between children of PD parents and healthy
parents may be due to a lack of sensitivity of the CASI. It has been suggested, that
the CASI is possibly still in need of some refinement to assess AS in children more
accurately (Lau et al.. 1996). In a nonclinical population, it was found that even
children with sporadic panic attacks did not differ in CASI scores compared to
nonpanickers (Calamari et al., 2001). Nevertheless, the CASI has a proven record
of discriminating between children with anxiety disorders and control children. It
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is therefore more likely that the present study, like Mannuzza et al.'s (2002), truly
reflects a normal level of AS in children of PD patients. It should be noted that
our sample of children, like that of Mannuzza et al., was quite young, with mean
ages of 11.9 and 11.5 years, respectively. It is possible that, AS is a developing
vulnerability factor that may increase as children get older; high AS only becom-
ing manifest beyond a certain age. Commenting on the failure of earlier studies to
find increased AS levels in anxious children (Rabian et al., 1993; Silverman et al.,
1991), Lau and colleagues (1996) pointed at the young age of the children in these
studies, and wondered whether AS in childhood may increase over time (Lau et al.,
1996). Recent research indeed demonstrates that there seem to be consistent pat-
terns of AS changes during childhood. In a 4-year longitudinal study of AS in high
school students, Weems et al. (2002) identified groups of adolescents with stable
low AS, stable high AS, or escalating AS. Most importantly, results showed that
youth with stable high AS or escalating AS were at increased risk for panic attacks
(Weems et al., 2002). It may well be the case that children of PD parents belong
to the group of youth with escalating AS levels. Stressors have been demonstrated
to elevate AS levels. In particular, the experience of spontaneous panic attacks in-
creases AS levels, especially when occurring during low levels of general distress
(Schmidt, Lerew, & Joiner, 2000). Although panic attacks do occur in a sizeable
proportion of normal adolescents (Lau et al., 1996), it is well-conceivable that
children of PD parents are particularly prone to suffer from either limited symp-
toms or full blown attacks. In this view, children of parents with PD will show
gradually increasing levels of AS during childhood, a hypothesis that clearly war-
rants further research. This would also imply that only in late adolescence and
early adulthood, high levels of AS should be considered as a significant risk factor
for PD, which may nicely fit the clinical observation that the peak age of onset for
PD is 25 years (American Psychiatric Association, 1994).
In conclusion, the results from the present study show that high AS, which
is considered as an important risk factor for PD, is not present in children of PD
parents, at the age of 11 years. AS in children of parents with PD might be an un-
derlying vulnerability factor, which is not clearly manifest until late adolescence
or early adulthood. Only further longitudinal studies will demonstrate whether
these children display escalating AS levels towards their early adulthood and sub-
sequently are more prone to develop PD themselves.
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Anxiety sensitivity and modulation of the
serotonergic system in patients with panic
disorder
Anxiety sensitivity, i.e., the fear of anxiety-related bodily sensations, is one of the
most studied cognitive variables in panic disorder. However, the effects of selec-
tive serotonergic antipanic agents on this variable have not yet been investigated.
The present study examines the effects of 6 weeks of treatment with citalopram
on anxiety sensitivity in patients with panic disorder. Twenty patients entered the
study. On day 0, before starting drug treatment, after 1 week and after 6 weeks
of treatment, each patient was evaluated with the Anxiety Sensitivity Index (ASI);
the severity of clinical symptomatology was assessed with standardized psycho-
metric scales. Results showed a significant reduction of anxiety sensitivity after 6
weeks of treatment. There was a significant correlation between decrease of anxi-
ety sensitivity and anticipatory anxiety, while no correlations were found between
panic attacks and agoraphobic avoidance. These results suggest that antipanic drug
treatment decreases anxiety sensitivity.
Romano, P., van Beek, N., Cucchi, M., Biffi, S. & Perna, G. (in press). Anxiety sensitivity and
modulation of the serotonergic system in patients with PD. ,/ourna/ o/Aariefy D/sorder.5
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Introduction
Anxiety sensitivity (AS) is a dispositional cognitive variable that reflects the fear
of anxiety-related bodily sensations that arise from beliefs that these sensations
have harmful consequences (Taylor, 1999). For example, subjects with high AS
may believe that a rapid heart rate signifies an impending heart attack, whereas
subjects with low AS will merely regard this as unpleasant (McNally, 1994). AS
is a construct conceptually distinct from trait anxiety (McNally, 1996; Rapee &
Medoro, 1994) and may be a cognitive risk factor for developing panic disorder
(PD) (McNally, 1994; McNally & Lorenz, 1987; Schmidt, Lerew, & Jackson,
1999). AS can be measured by the Anxiety Sensitivity Index (ASI) (Peterson &
Reiss, 1992; Reiss et al., 1986).
AS may be a predictor of the maintenance of PD in patients who remain un-
treated (Ehlers, 1995). Consequently, treating PD may have an impact on the level
of AS. Reductions in ASI scores of patients with PD following cognitive/behavioral
treatment (CBT) have already been reported (McNally & Lorenz, 1987; Shear,
Pilkonis, Cloitre, & Leon, 1994; Teich et al., 1993). These studies indicate that
exposure and cognitive restructuring interventions reduces AS. However, it is not
clear if an explicit focus on fear of anxiety is necessary for the modification of AS.
Other treatments, such as pharmacotherapy, may also lead to significant changes in
AS. It is possible that fear of anxiety sensations is maintained by presence of panic
attacks. If so, any treatment that controls these attacks might correspondingly di-
minish the fear of anxiety sensations. Alternatively, cortical serotonin changes
might change cognitions directly, i.e., without psychological mediation, as some
studies on depression have highlighted (Imber et al., 1990; Simons, Garfield, &
Murphy, 1984).
Few studies have examined the effects of pharmacotherapy on ASI scores; all
of these found a decrease of AS (Mavissakalian, Perel, Talbott-Green, & Sloan,
1998; Otto, Pollack. Sachs, Rosenbaum, & Fava, 1991). Otto et al. (1991) re-
ported a reduction of ASI scores from a mean of 31.3 at baseline to 22.2 after
6 months of drug treatment (67% of the sample with benzodiazepines alone, 8%
with antidepressants alone and 25% with a combination of the two drugs). Mavis-
sakalian et al. (1998) found that mean ASI scores decreased from 33.6 to 12.5 after
24 weeks of treatment with imipramine, with the mean score lower than 20 by 8
weeks. These studies suggest that fear of the consequences of anxiety-related bod-
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ily sensation can be normalized by biological treatments. Among the main brain
systems, several experimental evidences suggest that the serotonergic one plays
a key role in the pathogenetic mechanism of anxiety disorders, PD in particular
(Coplan, Gorman, & Klein, 1992; Gorman, Kent, Sullivan, & Coplan, 2000; Roy-
Byrne & Cowley, 1998), and the efficacy of selective serotonergic agents in the
treatment of PD supports the idea of an important role of the modulation system
in the treatment of PD (Kent, Coplan, & Gorman, 1998; Perna, Bertani, Caldirola,
Smeraldi, & Bellodi, 2001). We hypothesize that modulation of the serotonergic
system is able to improve not only the core symptoms of PD, but also the catas-
trophic misinterpretation of anxiety symptoms. To test this idea, we have evaluated
effects of 6 weeks of treatment with citalopram, the most selective drug for block-
ing serotonin reuptake, on AS in a sample of patients with PD. In addition, since
citalopram decreased anxious hypereactivity to inhalation of carbon dioxide (a bi-
ological marker of PD) as rapidly as the first week of treatment (Bertani, Caldirola,
Bussi, Bellodi, & Perna, 2001). we measured AS after 1 week (testing the idea that
cognition could change before clinical improvement).
Method > *•
Subjects
Twenty-two outpatients with PD were recruited over 12 months at the Anxiety
Disorders Clinical and Research Unit of the Department of Neuropsychiatric Sci-
ences from the San Raffaele Hospital in Milan. All patients were agoraphobics.
Two patients were withdrawn for poor tolerability and therefore were excluded
from the analysis. Twenty patients (6 males and 14 females; mean age = 28 years,
SD = 9.6; mean age at onset = 21 years, SD = 5.4) completed the study. Diagnostic
assessments were made by a senior psychiatrist of this study using the Schedule
for Affective Disorders and Schizophrenia, lifetime version, modified for the study
of Anxiety Disorders (SADS-LA-IV) (Fyer, 1995). Exclusion criteria for all sub-
jects included psychiatric disorders other than PD, significant medical diseases,
pregnancy, and epilepsy. Exclusions were made as a result of direct physical exam-
ination and careful collection of the medical history. Each patient gave informed
consent after a detailed explanation of the experimental procedure, carried out in
accordance with the Declaration of Helsinki, 1964, and its amendments (Tokyo,
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1975, Venice, 1983, and Hong Kong, 1989).
Drug treatment
Patients were treated with citalopram for 6 weeks. At the beginning of treatment
patients were given a daily dose of 10 mg for 1 week, 20 mg from day 8 to day
11, 30 mg from day 12 to day 14, and 40 mg from day 15 to the end of the trial.
No concomitant psychotropic drugs or psychotherapeutic interventions of any kind
were allowed during the trial.
Assessments
The psychometric scales were administered on days 0, the day of beginning med-
ication, 7, and 42 by experienced psychiatrists. The raters were others than the
authors and blind to the aim of the study and to the drug treatment. The same rater
evaluated each patient over time. The following scales were used:
• The Panic Associated Symptoms Scale (PASS) a self-administered scale to as-
sess frequency of panic attacks, level of anticipatory anxiety, and phobic avoid-
ance. Those yielded a global score (PASS-TOT), subscores for panic attacks
(PASS-AP), phobic avoidance (PASS-FOB), and anticipatory anxiety (PASS-
AA) (Argyle et al., 1991).
• The Fear Questionnaire (FQ) a self-administered scale assessing to value the
entity of the avoidant behavioral. A global score was obtained, with subscores
for agoraphobia (FQ-AGO), blood-injury phobia (FQ-BI), and social phobia
(FQ-SP) (Marks & Mathews, 1979).
• Anxiety Sensitivity Index (Peterson & Reiss, 1992) is a self-administered scale
developed to measure the fear of anxiety sensations on a five-choice continuum
(0 = no anxiety to 4 = maximum anxiety). The mean score of the ASI in healthy
subjects was 18.4 ± 8.5 (Peterson & Reiss, 1987) and, according to the score's
distribution, subjects were classified into three groups: with high (ASI score >
27), medium (10 < ASI score < 26) and low (ASI score < 9) AS.
• State Trait Anxiety Inventory (STAI) (Spielbergeret al., 1970) is a self-adminis-
tered scale to assess the state anxiety where subjects rate how they generally
feel on a four-point scale (1 = almost always).
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Data analyses
Fractional ranks was performed on the raw data before doing the analysis. To
assess the significances of any differences in continuously distributed variables
across the trial (days 0, 7, and 42) Friedman ANOVA tests and post-hocWilcoxon
matched pairs tests with Bonferroni's corrections were applied. For each variable,
the response to treatment was calculated as score (score on day 0 minus score on
day 42). Correlations between variables were analysed by Spearman rank correla-
tion tests.
Results
Citalopram was well tolerated by patients who completed the study (91%). The
two patients who withdrew the study reported nervousness, somnolence, gastroin-
testinal distress.
Table 6.1 reports scores on the psychometric scales before treatment, after 1
week and after 6 weeks of treatment with citalopram. Friedman tests showed a
significant decrease of scores for panic attacks, anticipatory anxiety and phobic
avoidance on the PASS scale, and for agoraphobia and blood-injury phobia sub-
scales of the FQ. Post-hoc Wilcoxon tests showed significant decreases of these
variables only after 42 days of treatment, while the decreases were not significant
after 7 days.
Table 6.1 Psychometric scores during treatment with citalopram
ASI
STA I
PASS-AP
PASS-AA
PASS-FOB
PASS-TOT
FQ-AGO
FQ-BL
FQ-SOC
DayO
mean =
26.6
52.6
4.2
3.3
1.1
8.7
15.2
19.8
10.4
±
±
±
±
±
±
±
±
±
bSD
8.7
12.6
2.6
1.8
.1
4.0
12.2
11.7
8.3
Day
mean d
23.2
50.4
3.6
2.6
0.95
7.2
15
20.5
10.3
±
±
±
±
±
±
±
±
±
7
:SD
9.5
13.2
1.9
1.5
.1
3.2
11.3
11.3
8.1
Day 42
mean ± SD
17.2
38.4
1.5
1.3
0.50
3.3
8.4
15.7
9.4
±
±
±
±
±
±
±
±
7.7
12.9
1.8
1.0
.9
3.3
9.2
9.8
10.0
Friedman ANOVA
(N=20. df=2)
* -=19 .7
^ = 1 5 . 3
r = !6.2
r = 16.8
r = 6.4
^ = 20.6
a r - = i i - i
** = 9.6
r = o.8
p<0.00005
p<0.0004
p< 0.0003
p< 0.0002
p<0.04
p<0.00003
p<0.002
p<0.008
p=NS
ASI scores on days 0, 7, and 42 are also reported in Table 6.2. Before treatment,
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10 patients (50%) had high ASI scores and 10 medium scores, while none had low
scores. The mean ASI scores before treatment were higher than those reported in
a sample of Italian normal controls (11.2 ± 6.4) (Saviotti et al., 1991). Friedman
tests showed a significant decrease of ASI scores across the trial. A post-hoc
Wilcoxon test with Bonferroni's correction showed a significant decrease from
day 0 to day 42 and from day 7 to day 42, while no significant decrease of ASI
scores was found from day 0 to day 7.
Table 6.2 Anxiety Sensitivity Index scores across treatment with citalopram
Day 0 Day 7 Day 42
34 22
36 23
9 12
16 17
27 17
20 12
15 12
31 20
31 27
26 11
1 1
22 4
28 28
41 21
20 19
15 11
26 27
17 14
23 19
26 28
The Spearman rank correlation test showed a significant correlation between ASI
and PASS-AA (r = .48, p < 0.04) and ASI and FQ-BF (10; r = .61, p <
0.005), while no significant correlations were found between ASI and PASS-
AP, PASS-FOB, FQ-AGO, FQ-SOC, and STAI. No significant correla-
tions were found between ASI scores before treatment and all the scores of the
PASS. FQ, and STAI scales.
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Subject 1
Subject 2
Subject 3
Subject 4
Subject 5
Subject 6
Subject 7
Subject 8
Subject 9
Subject 10
Subject 11
Subject 12
Subject 13
Subject 14
Subject 15
Subject 16
Subject 17
Subject 18
Subject 19
Subject 20
42
26
14
19
42
28
14
32
27
31
23
25
12
26
23
17
28
32
37
33
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Discussion
This is the first study examining the effects of a serotonin reuptake inhibitor on
AS in patients with PD. The results suggest that citalopram might decrease fear of
bodily sensations in patients with PD. Some significant limitations should be taken
into account when interpreting these results. This study was a simple pre-post
design, not placebo controlled. Therefore, given the importance of a placebo effect
in the treatment of patients with PD, we cannot exclude this bias in the explanation
of our results, although citalopram has been repeatedly demonstrated to be more
effective that placebo in the reduction of phobic symptoms (Leinonen, Lepola,
Turtonen, Wade, & Letho, 1990; Lepola, Leinonen, & Turtoten, 1994; Lepola
et al., 1998) and ASI scores are stable over time (Mailer & Reiss, 1992; Reiss et al.,
1986; Schmidt et al., 1999). The clinical utility of this study is limited from the
utilization of fixed dosages and the exclusion of individuals with episodes of major
depression. Moreover, the sample examined was not large enough to exclude the
possibility of Type II errors, and thus replication with larger samples is warranted.
Finally, since we have studied a sample of panic patients with agoraphobia, we
cannot exclude a different result in those without agoraphobia.
The main finding of the present study is the evidence that treatment with a
selective serotonergic agent improves not only the core somatic manifestations of
PD, but also the tendency to make misinterpretations of them. This finding gives
rise to two implications. First, the decrease of AS after drug treatment alone, con-
sistent with the two previous studies examining the effect of antipanic medications
on AS (Mavissakalian et al., 1998; Otto et al., 1991), challenges the idea that the
decrease of AS is selectively mediated by cognitive/behavioral treatment (Clark
et al., 1994). Second, since citalopram is a selective serotonergic compound, de-
crease of AS suggests that the serotonergic mechanism might be involved in mod-
ifying this cognitive aspect of PD. The serotonergic system, by decreasing activity
of the amygdala, could influence both cortical sites involved in the interpretation of
sensory information, and diminishes the activity of brainstem centers that activate
somatic symptoms during panic attacks (Gorman et al., 2000). The double modu-
lation might yield a therapeutic effect on both the somatic and cognitive aspects of
PD. Modulation of the serotonergic system might also be one mechanism through
which psychotherapy, in particular the cognitive/behavioral approach, could exert
a therapeutic effect in improving both somatic and cognitive aspects of PD (Baer,
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1996).
AS only decreased significantly after 6 weeks of citalopram treatment, whereas
the decrease after 1 week was not significant. This finding parallels the delay of the
improvement of core symptoms of PD panic attacks, agoraphobic avoidance and
anticipatory anxiety during drug treatment and suggests that the decrease in panic
symptoms might not be secondary to an immediate decrease of AS. However, only
an evaluation of these components at short intervals during the trial could provide
a definitive answer. Moreover, the absence of a significant correlation between the
decrease of AS and the decrease of panic attacks or agoraphobic avoidance after
1 week argues against a direct relationship between improvement of panic symp-
toms and cognitive fear of bodily-related symptoms. The positive correlations
between the decrease of AS (i.e., fear of anxiety-related bodily sensations), and of
both anticipatory anxiety (i.e., fear of having panic attacks) and blood-injury pho-
bia suggest that treatment with serotonergic drugs might influence a fear system
specifically involved in the emotional interpretation of bodily sensations.
Finally, in our sample, AS was not able to predict a decrease in any of the psy-
chometric measures of the severity of PD, suggesting that fear of anxiety-related
bodily sensations is not related to the response to serotonergic antipanic drugs.
Future research should include a placebo control group and a non-PD group to
investigate the specificity of our finding. Moreover, it might also be interesting to
investigate whether treatment with effective antipanic agents other than citalopram
would result in a similar decrease in AS.
In conclusion, the results of our study indicate that serotonergic antipanic com-
pounds might decrease AS. The decrease of AS seems to be related to the decrease
of anticipatory anxiety as there were no correlations with a decrease in panic at-
tacks and agoraphobic avoidance.
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Prevalence of respiratory disorders in
first-degree relatives of panic disorder
patients
Panic disorder patients often report a history of respiratory pathology, such as
asthma. Also, it has been repeatedly demonstrated that panic disorder is highly
prevalent amongst patients with respiratory disorders. It is known that both panic
disorder and respiratory disorders, like asthma, run in families. A common diathe-
sis for panic disorder and respiratory disorders may be present both in panic dis-
order patients and their first-degree relatives. We examined whether the lifetime
prevalence of respiratory disorders is higher in first-degree relatives of panic dis-
order patients than in first-degree relatives of patients with other anxiety disorders.
The lifetime history of respiratory pathology was assessed in 379 first-degree
relatives of patients with an anxiety disorder by means of a questionnaire. We
found the first-degree relatives of panic disorder patients (n = 258) to report sig-
nificantly more chronic obstructive pulmonary diseases (COPD) in general and
asthma specifically than the control group (n = 121). Our findings are consistent
with and extend previous studies by showing that a specific association between
COPD, asthma in particular, and panic disorder may exist.
van Beek, N., Schmers. K. & Griez, E. (submitted). Prevalence of respiratory disorders in first-
degree relatives of panic disorder patients.
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Introduction
There is an obvious overlap in symptomatology between panic and respiratory dis-
orders. Both disorders have dyspnea, smothering sensations and choking in com-
mon. Furthermore, anxiety, a predominant symptom of panic disorder (PD), fre-
quently occurs in asthmatic patients (Carr, 1999; Smoller et al., 1996). However,
the link between both types of pathology seems to go beyond a mere phenomeno-
logical resemblance. Research has now repeatedly demonstrated that PD is highly
prevalent amongst patients with asthma and other chronic obstructive pulmonary
diseases (Carr, 1998; Karajgi et al., 1990; Nascimento et al., 2002; Pollack et al.,
1996; Yellowlees et al., 1987; Yellowlees. Haynes, Potts, & Ruffin, 1988).
Conversely, we (Zandbergen et al., 1991) and others (Perna et al., 1994; Spin-
hoven et al., 1994) have repeatedly found adult PD patients to report a signifi-
cantly higher lifetime and childhood prevalence of respiratory disorders than con-
trol groups. The prevalence of respiratory disorders before the onset of the anxiety
disorder was found to be as high as 42.7% in PD patients contrasting with only
16.2% in controls (Verbürg, Griez, Meijer, & Pols, 1995b). Congruently with
these findings, a recent large scale epidemiological study showed asthma, chronic
bronchitis, or emphysema to be related to an increased risk of developing panic
attacks in adulthood (Goodwin & Pine, 2002).
Investigating the lifetime history of atopic disorders in the offspring of PD
parents, a recent study suggested an increased rate of asthma in children of PD
patients (Slattery et al., 2002). Both PD (Crowe et al.. 1983; Goldstein et al., 1997;
Maier et al., 1993; Torgersen, 1983) and atopic disorders, such as asthma (Hopper
et al., 1990; Postma & Kips, 1999) have been known to rely on a constitutional
predisposition which runs in families. PD patients and their first-degree relatives
may share a diathesis that predisposes them to both types of pathology. If that is
the case, one would predict the lifetime prevalence of respiratory disorders, atopic
disorders such as asthma in particular, to be higher in first-degree relatives of PD
patients than in first-degree relatives of patients with other anxiety disorders. This
hypothesis was investigated in the present study.
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Method
Participants
Three hundred seventy nine first-degree relatives of patients with an anxiety dis-
order referred to our Academic Anxiety Center in Maastricht agreed to participate
in the present study. Amongst them. 258 were relatives of patients with a DSM-
IV diagnosis of PD and 121 of patients with another DSM-IV anxiety disorder.
All patients' diagnoses were made by experienced clinicians on basis of the Mini
International Neuropsychiatric Interview (Sheehan et al., 1997). First-degree rela-
tives of patients not fulfilling the criteria for one of the anxiety disorders according
to DSM-IV; having PD and a comorbid anxiety disorder; and only having agora-
phobia were excluded from the study. Since our main interest was in the relation
between asthma and PD, one could consider asthma in patients as a confounder.
Therefore, we excluded the family members of patients who ever reported asthma
both in the PD and non-PD group.
Procedure ^
After having obtained the informed consent from both the patient and his or her
relative, all participants completed a specially developed questionnaire, either on
basis of a telephonic interview or by returning the mailed questionnaire. As far
as children younger than 16 were concerned, data were collected with the parents'
collaboration.
The questionnaire globally assessed the lifetime prevalence of any type of sig-
nificant respiratory disorder, excluding trivial affections, such as common cold.
The questionnaire specifically assessed the following categories: asthma, bronchi-
tis, emphysema, and 'other disturbances affecting the respiratory system'. Each
category on the questionnaire was scored as present ('ever suffered from') or ab-
sent ('never had this type of disease") on a lifetime basis.
Data analyses
We organized the data in three different ways with increasing specificity: 'any type
of dysfunction affecting the respiratory apparatus' (which meant any positive an-
swer in whatever category of the questionnaire), 'chronic obstructive pulmonary
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diseases' (COPD: i.e., asthma, bronchitis, emphysema (Goodwin & Pine, 2002)),
and finally the discrete categories of asthma, bronchitis and emphysema. Presence
or absence of a score in each of the above categories was assessed in first-degree
relatives of PD patients versus those of patients with other anxiety disorders. Fi-
nally, data from children under the age of 16 were specifically addressed. Data was
analyzed using a Chi-square test with Yates' continuity correction, except when
the assumptions for a Chi-square test were not met, a Fisher exact test was used.
Results
The total group of first-degree relatives of PD patients (n = 258, mean age = 32.5
years, SD = 22.5) did not differ in age from the total group of first-degree relatives
of other anxiety disorder patients (n = 121, mean age = 34.8 years, SD = 21.8)
(t(374) = -.95, p = NS). The children of PD patients (n = 95) had a mean age of
9.4 years (SD = 4.1) and the other child group (n = 37) scored 8.9 years (SD =
4.2). This difference was not statistically significant (t(130) = .66, p = NS).
Ninety-five of the 258 first-degree relatives of PD patients (36.8%) versus 37
of the 121 first-degree relatives of other anxiety disorder patients (30.6%) reported
a lifetime prevalence of any respiratory disorder. This difference did not reach sta-
tistical significance (#- = 1.2, p = NS). Sixty-four of the 258 first-degree relatives
of PD patients (24.8%) reported a lifetime prevalence of COPD compared to 16 of
the 121 control first-degree relatives (13.2%). This difference on COPD was sta-
tistically significant ( ^ = 6.0, p < 0.05). To further refine the subcategory COPD,
we calculated the prevalence of asthma, bronchitis and emphysema. Asthma oc-
curred in 27 of the 258 first-degree relatives of PD patients (10.5%) versus only in
4 of the 121 first-degree relatives of other anxiety disorder patients (3.3%). This
difference on asthma was also statistically significant (#- = 4.71, p < 0.05) (Fig-
ure 7.1). Although the prevalence of bronchitis (13.2% vs. 9.1%) or emphysema
(1.2% vs. 0.8%) in the first-degree relatives of PD patients was higher than that
in those of other anxiety disorder patients, the differences were not statistically
significant.
Thirty-nine of the 95 children of PD patients (41%) and 12 of the 37 children
of other anxiety disorder patients (32.4%) had any respiratory disorder (#- = .51,
p = NS). Twenty-two out of the 95 children of PD patients (23.2%) reported a
lifetime prevalence of COPD versus 6 of the 37 children of other patients (16.2%)
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• First-degree relatives of PD patients
D First-degree relatives of other anxiety disorder patients
Any respiratory
disorder
COPD
Figure 7.1 Prevalence (%) of respiratory disorders in first-degree
relatives
(£- = .41, p = NS). On the subcategory asthma, a lifetime occurrence was reported
by 13 of the 95 children of PD patients (13.7%) compared to 4 of the 37 controls
(10.8%) (p = NS, Fisher exact test) (Figure 7.1). The children groups did not differ
in prevalence of bronchitis (9.5% vs. 5.4%) or emphysema (0% vs. 0%).
Discussion
Whether expressed as the global occurrence of any type of respiratory pathology
in general, or as the pooled occurrence of asthma, bronchitis and emphysema,
the lifetime prevalence of diseases affecting the respiratory system was higher in
first-degree relatives of PD patients than in first-degree relatives of other anxiety
disorder patients. The differences between these two groups reached statistical
significance for the pooled COPD category as well as for asthma specifically.
The difference between the first-degree relatives of PD patients and the con-
trol group however, did not reach statistical significance on the prevalence of res-
piratory pathology in general. In this regard, it should be noted that this global
measure included the category "other disturbances affecting the respiratory sys-
tem" in our self designed questionnaire, resulting in a very rough approach of
respiratory pathology. Under the broad formulation of this latter category, par-
ticipants appeared to report such various conditions as infectious diseases, for in-
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stance acute pneumonia, and mechanical incidents of false deglutition causing a
suffocation-like experience. Thus, it may be supposed that the global evaluation
of respiratory diseases, as assessed by our questionnaire, took into account very
heterogeneous conditions, some of them being only loosely linked to respiratory
physiology. Therefore, as far as 'respiratory pathology in general' is concerned,
we suspect background noise to have masked a statistically significant difference
between the first-degree relatives of PD patients and the control group.
Narrowing the diagnostic focus on COPD, we found the data to be consistent
with our expectations. First-degree relatives of PD patients had a significantly
higher lifetime prevalence of obstructive respiratory diseases than family mem-
bers of other anxiety disorder patients. This result is consistent with, and extends
repeated findings of a series of earlier studies reporting an association between
PD and COPD (Perna et al., 1994; Verbürg et al., 1995b; Yellowlees et al., 1987;
Zandbergen et al., 1991).
Considering the fact that a more specific link between PD and asthma in par-
ticular has been suggested by others (Carr, 1999; Perna, Bertani, Politi, Colombo,
& Bellodi, 1997) and that the prevalence of asthma has doubled in ten years in
Western Europe (Steerenberg et al., 2000), we paid special attention to the dis-
crete category of asthma. Similarly to COPD in general, there was a significant
difference in the prevalence of asthma between PD families and families of other
anxiety patients. Eleven percent of the first degree relatives of PD patients reported
a lifetime history of asthma while only 3% of comparison family members did so.
Regarding the children under the age of 16, the figures are in general remark-
ably comparable to those observed in the groups of adult first-degree relatives.
However, the differences between children of PD patients and those of parents
with other anxiety disorders failed to reach statistical significance, probably due
to a limited number of participants in the latter group. Nevertheless, compared
to those of other anxiety disorders parents, children of PD parents suffer twice as
often from bronchitis. Also, the prevalence of asthma we found in children of PD
patients was over twice as high the prevalence of 6% in a Dutch sample of school
children (Rijcken, Schouten, & Kerkhof, 1999). This might suggest that being a
child of a PD parent makes one especially vulnerable to develop respiratory con-
ditions, like bronchitis and asthma.
The above findings indicate a common familial aggregation of some types of
respiratory diseases and PD. Conclusions about the sequence of onset of respira-
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tory disorders and PD cannot be drawn from our data, let alone about any link of
causality between respiratory and affective pathology. Beside the hypothesis of a
shared diathesis, predisposing both to PD and obstructive respiratory pathology, it
is possible that some types of respiratory conditions predispose to the development
of PD. A strong argument in favor of this idea is the finding that asthma and other
obstructive conditions do represent an increased risk of panic attacks (Goodwin
& Pine, 2002). Moreover, personal experience with trivial wheeze and asthma at
age 15 increased the risk for PD in females, just as a positive history for asthma
at age 18 increased the risk for PD in more emotionally reactive males (Craske,
Poulton, Tsao, & Plotkin, 2001). It is worth noting that asthma or other obstruc-
tive respiratory conditions involve the presences of relatively prolonged respiratory
dysfunction with dyspnea as a prominent feature. Panic has been conceived as the
consequence of an oversensitive biological suffocation alarm (Klein, 1993). One
might speculate that a chronic obstructive respiratory condition presenting in the
early childhood induces a lowering of this putative suffocation alarm threshold via
a process of long-term sensitization. However, as long as the exact sequence of
onset has not been established in large scale prospective longitudinal studies, the
nature of the relation between both types of pathologies will remain speculative. A
particular focus of interest should be the population of children of PD parents who
are suffering with asthma or bronchitis, since, according to the above speculations,
those subjects are expected to be at high risk for the development of PD later in
life.
While either a shared diathesis, or a simple causal link between PD and COPD
may be an obvious, albeit speculative, hypothesis, one could think of other factors
entering into play. Passive smoking is known to be of importance in the develop-
ment of asthma during childhood (Rijcken et al., 1999). PD patients smoke more
cigarettes than persons in the general population and individuals with other anxi-
ety disorders (Zvolensky, Schmidt, & Stewart, 2003). Therefore, close relatives of
PD patients are at higher risk than others to be exposed to the pathogenic effects
of passive smoking, at least those first-degree relatives living together with the PD
patient. Moreover, it has been suggested that cigarette smoking itself contributes
to the development of PD (Zvolensky et al., 2003). Findings of a large epidemio-
logical study indicate that daily smoking was associated with an increased risk for
first-time occurrence of panic attacks and PD (Breslau & Klein, 1999). In addi-
tion, heavy cigarette smoking during adolescence was found to be associated with
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an increased risk for PD during early adulthood (Johnson et al., 2000). Therefore,
the factor of smoking may be a good candidate to explain an aggregation of PD
and (childhood) asthma in the same families.
Some limitations of the present study should be mentioned. First, the data on
respiratory disorders relies on retrospective self-reports. At best, this is likely to
represent a crude approximation of the exact history of respiratory disorders. To
reduce the effect of a possible recollection bias, we used only rough diagnostic
categories. Patients are likely to remember if they ever have had any respiratory
disorder, but they may be expected to have difficulty remembering exactly what
kind of diagnosis was made. This crude approach introduced diagnostic impreci-
sion and prevents refined analysis. On the other hand, self-reports are the most
commonly used form of assessment of physical diseases in large surveys, which
allows for comparison of prevalence rates (Goodwin & Pine, 2002). Second, our
PD patients were assumed to contact first-degree family members who were not
under psychiatric treatment. However, the participating relatives did not undergo
formal psychiatric assessment and therefore it cannot be excluded that they were
free of any psychiatric disorder.
Despite the above limitations, we found quite strong evidence that first-degree
relatives of PD patients have a higher prevalence of respiratory pathology, in par-
ticular COPD, than those of patients with other anxiety disorder. This finding adds
to the suspicion that a link may exist between COPD, namely asthma, and PD.
Future studies that further examine affected families and analyze the sequence of
onset of both types of diseases will help improving our understanding of this co-
morbidity.
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Vulnerability to 35% CO2 of panic disorder
patients with a history of respiratory
disorders
Patients with panic disorder often report a history of respiratory pathology. Fur-
thermore, panic disorder patients are vulnerable to COT challenges. The increased
COi vulnerability displayed by panic disorder patients may be related to lifetime
respiratory pathology. We examined whether panic disorder patients with a history
of respiratory disorders are more vulnerable to a 35% COT challenge than those
without such a history. Ninety-six patients with panic disorder were interviewed
about their lifetime respiratory status (asthma, bronchitis and various other res-
piratory conditions) and underwent the challenge. Immediately before and after
the CO: inhalation, the patients rilled out the Visual Analogue Scale for Anxiety
(VAS-A) and the Panic Symptom List (PSL). We found no differences between the
two panic disorder groups on anxiety (VAS-A), panic symptoms (PSL) or panic
attacks after the CO2 challenge. Our results support that having a panic disorder
is an important factor in COi vulnerability independent of a history of respiratory
disorders.
van Beek, N., Perna. G.. Schmers, K., Verbürg, K., Cucchi, M., Bellodi. L., & Griez, E. (in press).
Vulnerability to 35% CCb of panic disorder patients with a history of respiratory disorders.
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Introduction
Several studies suggest a link between panic and respiratory disorders. Panic dis-
order patients, either with or without agoraphobia (PD), more often report a history
of respiratory disorders compared to other populations (Perna et al., 1994; Spin-
hoven et al., 1994; Zandbergen et al., 1991). The lifetime prevalence of respiratory
diseases was significantly higher in PD than in obsessive compulsive disorder and
eating disorder patients (Zandbergen et al., 1991). Conversely, a higher prevalence
of PD was found in patients with chronic obstructive pulmonary diseases than in
the general population (Karajgi et al., 1990; Yellowlees et al., 1987). Asthma is
associated with a high risk of panic attacks and panic symptoms (Carr, 1999). Fur-
thermore, symptoms of panic attacks overlap with the respiratory distress seen in
some pulmonary diseases (Smoller et al., 1996).
Experimentally, PD patients are hyperreactive to inhalation of hypercapnic gas
mixtures, while COT is a well-known key factor in respiratory regulation. Specif-
ically, PD patients are more vulnerable to a 35% CO2 challenge than healthy sub-
jects (Griez et al., 1987; Fyer et al., 1987; Perna et al., 1994), patients with mood
disorder (Perna et al., 1995), obsessive compulsive disorder (Griez et al., 1990;
Perna et al., 1995), generalized anxiety disorder (Verbürg et al., 1995a), and other
psychiatric disorders (Griez et al., 1990; Papp et al., 1993). Particularly, it is hy-
pothesized that PD patients have an abnormally low suffocation alarm threshold
and that panic attacks may be the equivalent of a false alarm triggered in an over-
sensitive suffocation monitor (Klein, 1993).
However, not all PD patients are equally vulnerable to 35% COT. Depending
on the criteria used, up to 52% of them fail to report a panic attack in response to
a 35% CO2 challenge (Gorman et al., 1990; Perna et al., 1994, 1995). CO: vul-
nerability is not equally distributed across the PD population and may vary across
subtypes of PD. When PD patients were divided into a 'respiratory' and a 'non
respiratory' subtype according to the symptom profile of their panic attacks, the
'respiratory' group was significantly more sensitive to CO2 than the 'non respira-
tory' group (Biber & Alkin, 1999).
Overall, the increased CO2 vulnerability seen in PD patients may be related
to respiratory pathology. We therefore investigated whether PD patients with a
history of respiratory disorders are more vulnerable to a 35% CO2 challenge than
PD patients without such a history.
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Method
Subjects
Ninety-one patients with PD (with or without agoraphobia) participated in the
present study (49 men and 42 women; mean age = 35.9 years, SD = 11.0, range
18-64 years). Forty-four patients were recruited at the Academic Anxiety Cen-
ter in Maastricht (the Netherlands) and 47 at the Anxiety Disorders Clinical and
Research Unit, San Raffaele Hospital in Milan (Italy).
Inclusion criteria were: age between 16 and 65 years, no prior experience
with the COT challenge, a DSM-IV diagnosis panic disorder with or without ago-
raphobia. Diagnoses were made in good agreement by at least two experienced
clinicians using a structured interview (Mini International Neuropsychiatric Inter-
view; Sheehan et al., 1997). Exclusion criteria were: any comorbidity on axis I;
significant history of cardiovascular or cerebrovascular pathology; any current res-
piratory disorders, including asthma and lung fibrosis; personal or familial history
of cerebral aneurysm: hypertension with systolic pressure > 180 mmHg or dias-
tolic pressure > 100 mmHg; pregnancy; epilepsy. At the time of the challenge,
none of the subjects were on any centrally acting drugs. •*
Procedure
The study was approved by the local medical ethics committees both in Maastricht
and in Milan. After complete description of the study to the subjects, their in-
formed consent was obtained. The individual history of respiratory disorders was
assessed by means of a checklist. The checklist contained the items asthma and
bronchitis, and various other respiratory conditions (e.g., tuberculosis, recurrent
upper respiratory tract infections, and emphysema). On a positive answer, patients
were asked when the disorder occurred, if and how it was treated, and if there were
any further particularities. A patient was considered having a history of respiratory
disorders if he reported having suffered from any of the respiratory conditions. We
used this composite measure to reduce the effect of a possible recollection bias.
Patients are likely to remember if they had suffered from a respiratory disorder,
but they may have difficulty remembering exactly which diagnosis was made.
In both Maastricht and Milan the same CO2 inhalation procedure was used
(Verbürg et al., 2001). A gas mixture of 35% CO2 and 65% O2 was used. The
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gas was inhaled through a self-administration mask. The respirometer connected
to the self-administration mask measured the gas volume delivered at each inhala-
tion to ensure that at least 80% of the subject's vital capacity volume would be
inhaled. Subjects were informed that they would inhale a physiologically harm-
less gas mixture, but also that during the challenge they might experience some
discomfort, ranging from a few neurovegetative symptoms to strong anxiety-like
symptoms. The term 'panic attack' itself was not mentioned. A single vital-
capacity breath of the 35% CO2/65% O2 gas mixture was inhaled, and exhaled
after 4 seconds.
Self-administered questionnaires that the subjects rated immediately before
and after the inhalation were a Visual Analogue Scale for Anxiety (VAS-A) for
subjective anxiety, ranging from 0 to 100, and a 13 items Panic Symptom List
(PSL) referring to the DSM-IV criteria, each item being assessed on a 5-point
scale.
Data analyses
To determine whether the CO2 inhalation induces more subjective anxiety (VAS-
A) and panic symptoms (PSL) between the respiratory group and the non respi-
ratory group a repeated measures analysis of variance (ANOVA) was used with
history of respiratory disorders (Group) as between-subjects factor and the effects
of the challenge (Moment; pre or post) as within-subjects factor.
A CCh-induced panic attack was defined by an increase of anxiety (VAS-A
post CO2 > 25) combined with an increase in panic symptomatology (Pols et al.,
1996; Woods et al., 1990). A Chi-square analysis with Yates' continuity correction
was applied to determine if more PD patients with a respiratory disorder had more
CC>2-induced panic attacks than those without respiratory disorders.
Results
History of respiratory disorders
Fifty-seven PD patients (62.6%) had a history of respiratory disorders (respiratory
group; 31 men, 26 women, mean age = 35.4 years, SD = 9.4) and 34 patients
(37.4%) did not (non respiratory group: 18 men. 16 women, mean age = 36.9
years, SD = 13.4). The respiratory group did not significantly differ in age (t(52.6)
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= —.59, p = NS) or gender (#^ with Yates' continuity correction = .01, p = NS).
Nineteen patients had bronchitis, five patients had asthma, 13 had pneumonia and
66 had other respiratory conditions like, allergy or tuberculosis.
Subjective anxiety
The scores on the VAS-A are shown in figure 8.1. A significant main effect was
found for moment (F(l,89) = 174.5, p < 0.0001), meaning that a difference is
found in subjective anxiety pre and post the COT challenge for the entire group.
No significant main effect was found for group. No significant interaction effect
was found for group x moment.
• pre CO2 D post CO2
Respiratory group Non respiratory group
Figure 8.1 Scores (+SD) on the Visual Analogue Scale for Anxiety
(VAS-A) on the 35% CO2 challenge in panic disorder patients with
(Respiratory) and without a history of respiratory disorders (Non
respiratory)
Panic symptoms
The scores on the PSL are shown in figure 8.2. A significant main effect was
found for moment (F(l,89) = 148.0, p < 0.0001), meaning that a difference is
found in panic symptoms pre and post the CO2 challenge for the entire group. No
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significant main effect was found for group. No significant interaction effect was
found for group x moment.
• pre CO2 D post CO2
35
30
25-1
20
15
10
5
0
16.6
Respiratory group Non respiratory group
Figure 8.2 Scores (+SD) on the Panic Symptom List (PSL) on the
35% CO2 challenge in panic disorder patients with (Respiratory)
and without a history of respiratory disorders (Non respiratory)
CC^-induced panic attacks
Forty-eight PD patients with a history of respiratory disorders (84.2%) and 28
PD patients without a history of respiratory disorders (82.4%) had a COi-induced
panic attack. No significant difference was found in CO2-induced panic attacks
between the two groups.
Discussion
The results of the present study do not support the idea that PD patients with a
history of respiratory disorders are more vulnerable to the CO2 challenge than pa-
tients without such a history. The groups differed neither on CO^-induced anxiety,
nor on experimental panic symptoms, and nor on CO2-induced panic attacks.
There have been other attempts to link either current respiratory symptoms or
past pulmonary diseases with the higher than usual CCh vulnerability in PD. Biber
and Alkin (1999) classified 51 PD patients according to the symptom profile of
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their natural panic attacks. This was based on the way subjects experienced their
symptoms. Those reporting strong respiratory symptomatology were considered
to represent a 'respiratory' subtype of PD. It was found that 79% of the 'respira-
tory' subtype had a COi-induced panic attack versus only 48% of the 'non respi-
ratory' subtype (Biber & Alkin, 1999). However, there might be no relation at all
between the current symptom profile of panic attacks and a past history of respira-
tory disorders. In a previous experiment in the Maastricht laboratory, PD patients
were divided into 33 subjects with severe respiratory symptoms during panic at-
tacks ('respiratory' subtype) and 49 patients with moderate or minor breathing
complaints ('non respiratory' subtype). This classification resembles Biber and
Alkin's procedure. There was no relation between the two subtypes and history of
respiratory diseases (Verbürg et al., 1995b). Our present results suggest that, while
a current 'respiratory' profile of real life panic attacks may indicate a higher CO2
vulnerability, a lifetime history of respiratory diseases does not.
There is an increased lifetime prevalence of respiratory disorders in PD (Perna
et al., 1994; Spinhoven et al., 1994; Zandbergen et al.. 1991) and a history of
respiratory disorders has been linked to a higher probability of developing PD in
subjects with familial predisposition to PD (Perna et al., 1997). On the other hand,
CO2 vulnerability is a specific marker of panic (Verbürg et al., 1998). It runs in
families (Bellodi et al.. 1998; Perna et al., 1995; Van Beek & Griez. 2000) and
apparently identifies those individuals at risk for PD (Coryell. 1997). However,
results of the present study suggest that respiratory pathology early in life is not
directly linked to an increased CO2 vulnerability. Present CO2 vulnerability does
not merely result from past respiratory diseases, neither do past respiratory disor-
ders add to present CO2 vulnerability. Hence, even though they may have suffered
from more respiratory pathology than others, adult PD patients have no grossly
disturbed ventilatory physiology (Gorman et al., 2001). PD patients showed no
impairments in their pulmonary function (Carr. Lehrer. & Hochron, 1992; Ver-
bürg. De Leeuw, Pols. & Griez. 1997) and only a proportion of PD patients had
subclinical impairments in lung function (Perna et al., 1994). The relation between
history of pulmonary pathology, CO2 vulnerability, and PD may be more complex
than a simple causal sequence.
Alternative explanations are possible. It is conceivable that both the propensity
to early respiratory disorders and increased vulnerability to CO2 are linked to a
third factor governing the development of PD in adulthood. Alternatively, the role
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of respiratory pathology in increasing the possible risk of developing PD may be
less specific than once thought. A high prevalence of PD was not only found
in respiratory patients: PD is also highly prevalent in fibromyalgia (Malt, Berle,
Olafsson, Lund, & Ursin, 2000) and cardiovascular patients (Fleet et al., 2000;
Griez et al., 2000). While a high prevalence of PD was expectedly found in patients
with asthma, these subjects also reported an increased frequency of social phobia,
generalized anxiety disorder, and depression (Nascimento et al., 2002).
Notwithstanding, and even though the exact link between respiratory pathol-
ogy and PD is not clear, special mention should be made of asthma. In a large
sample of 3032 adults in the general population, a composite measure of the self-
reported diseases asthma, chronic bronchitis or emphysema was associated with
an increased likelihood of panic attacks. This specific association to panic attacks
persisted after adjusting for differences in sociodemographic characteristics, phys-
ical illnesses, and comorbid mental disorders (Goodwin & Pine, 2002). Other
investigators have also found a specific relation between panic attacks and asthma
(Carr, 1999; Perna et al., 1997). In light of a specific association between asthma
and PD, it should be interesting to investigate the COi vulnerability of PD patients
with a history of asthma compared to PD patients with a history of other respiratory
disorders.
The most obvious limitation of the present study lies in the retrospective char-
acter of the obtained data of the patient. It is possible, that there is a considerable
time-gap between the actual respiratory disorder and the data collection. Since
this data gathering was based on self-report, a recollection bias cannot be ex-
cluded. Being aware of this problem, we refrained from further refined diagnosis.
This obviously introduced another limitation, preventing more refined analysis on
basis of specific respiratory disorders.
To conclude, our findings indicate that PD patients with a history of respira-
tory disorders are not more vulnerable to the 35% CCh challenge than PD patients
without such a history, suggesting that there is no simple direct causal link be-
tween lifetime respiratory pathology and the observed CO2 vulnerability in adult
PD patients.
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Concluding remarks
The objective of this thesis was to investigate a number of vulnerability factors
in PD patients and their first-degree relatives. After having offered a general in-
troduction about PD, the factor COi sensitivity was examined empirically in the
second chapter. Cognitive as well as physiological factors may enter into play to
explain this COi sensitivity. The cognitive factor anxiety sensitivity (AS) was stud-
ied in the first part of the thesis. The last chapters addressed some issues related to
the role of respiratory pathophysiology. In the current chapter, the main findings
will be discussed and some directions for future research will be proposed.
Main results
• First-degree relatives of PD patients were more reactive to a 35% CO2 challenge
than healthy control participants.
• AS, which has been proposed as a risk factor for the development of PD, was
higher in first-degree relatives of PD patients than in healthy control partici-
pants, but not as high as in PD patients.
• However, and specifically, young children of PD patients were not more anxiety
sensitive compared to children of healthy parents.
• AS levels of PD patients decreased after a SSRI treatment of 6 weeks.
• First-degree relatives of PD patients have a significantly higher prevalence of
COPD, asthma in particular, than first-degree relatives of other anxiety disorder
patients.
• PD patients with a history of respiratory disorders were not more reactive to a
35% CO2 challenge than those without such a history.
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CO2 and anxiety sensitivity
It has been established that the 35% COi challenge is a valid laboratory model
for panic attacks. The results of the study described in Chapter 2 revealed that
healthy first-degree relatives of PD patients were more vulnerable to the 35% COT
challenge than healthy control participants. The cognitive factor AS may explain
this vulnerability to CCK The CO2 challenge may provoke sensations feared by
highly anxiety sensitive first-degree relatives. Therefore, we first examined in
Chapter 4 if first-degree relatives of PD patients have elevated AS levels at all.
Results showed that first-degree relatives of PD patients without lifetime panic
attacks indeed did have significantly higher levels of AS than control subjects. It
has been proposed that high AS is a risk factor for the development of PD. Yet,
increased AS is not a sufficient condition to develop a PD, since these first-degree
relatives, all of whom never had PD, had a mean age of 50, well above the peak of
onset for PD, and therefore were not likely to develop a PD anymore.
In Chapter 5 a subset of first-degree relatives of PD patients was examined
with regard to AS. Somewhat unexpectedly, children of PD patients, who are likely
to be more at risk for developing PD than older first-degree relatives, were not
more anxiety sensitive than children of healthy parents. Thus, parental PD pathol-
ogy does not seem to lead to high AS in their young children. Nevertheless, it may
be the case that learning experiences may strengthen or weaken the level of AS in a
person. It might therefore be possible that the level of AS in children can increase
over time. In line with this, other investigators have found in a prospective study
that ASI scores in adolescents did indeed increase over time (Weems et al.. 2002).
Thus, results from Chapter 5 suggest that AS might be a developing vulnerabil-
ity factor in children of PD patients that may increase towards late adolescence
or early adulthood. Only prospective studies could demonstrate whether in chil-
dren of PD patients AS levels do escalate. Whatsoever, the putative mechanisms
underlying an increased AS level over time warrant more investigation.
High levels of AS have been repeatedly found in subjects who have devel-
oped a PD. AS scores seem to be subject to change. Conceivably, if AS levels
can increase over time, it can decrease as well. Therefore, we studied whether
treatment with citalopram, a SSRI. has an effect on AS levels in PD patients. Re-
sults showed a significant decrease of AS levels after pharmacological treatment
in these patients (Chapter 6).
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The provisory conclusion from the preceding studies may run as follows. Being a
first-degree relative of a patient with PD is, in itself, an important factor in COi
vulnerability, even in the absence of any lifetime history of panic. This strongly
suggests that COT vulnerability may be a marker of a familial vulnerability to PD.
AS may run in PD families as well. It is conceivable that an elevated AS level in
first-degree relatives of PD patients is a vulnerability factor for both CO2 sensitiv-
ity and the development of PD. If so, AS is a risk factor that slowly develops over
time. Primary prevention might be adjusted to counter this development.
CO2 and respiratory pathology
The literature already abounds in evidence suggesting an association between res-
piratory disorders and PD. Respiratory disorders and panic attacks each are lead-
ing causes of disability and heath-care utilization among youth and adults in the
community (Kouzis & Eaton, 2000; Steerenberg et al., 2000). It is possible that
treatment of one can prevent exacerbation of the other. Consequently, improving
our understanding of the possible relation between respiratory diseases and PD is
important. Therefore in Chapter 7, the prevalence of respiratory disorders in PD
families was investigated. We found the first-degree relatives of PD patients to re-
port more COPD, asthma in specific, than those of other anxiety disorder patients.
Given the fact that both PD and asthma run in families, our findings may suggest a
specific association between asthma and PD. The mechanism of this observed link
still remains unclear. Besides the factor of smoking, which has been discussed ear-
lier, it might be the case that high AS plays a role in this association we have seen.
High AS runs in PD families (Chapter 4), and is related to subsequent development
of panic attacks (Schmidt et al., 1999). Strikingly, asthmatic patients reported sig-
nificantly higher ASI scores than healthy control subjects (Caccappolo-van Vliet,
Kelly-McNeil, Natelson, Kipen. & Fiedler, 2002). It is therefore conceivable that
AS as well may act as a moderating variable in the association between PD and
asthma. Whether in particular first-degree relatives of PD patients with asthma
display higher AS levels than others, requires however further investigation.
In our most recent study presented in Chapter 8, the link between respiratory
pathology and PD has been further examined. The hypothesis was tested whether
PD patients with a history of respiratory disorders are more vulnerable to a 35%
CO2 challenge than those without such a history. The results did not yield any evi-
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dence for a different response of PD patients with a history of respiratory disorders
to the CO2 challenge. We can conclude from this study that a history of respira-
tory disorders is not a crucial factor in CO2 vulnerability in PD patients. Despite
its suspected link with respiratory pathology, PD is in itself the most important
factor for a high CO2 vulnerability.
Conclusion
To conclude, CO2 sensitivity appears to be a marker of a vulnerability to PD.
Both AS and respiratory pathology, asthma in particular, might mediate this CO2
sensitivity and seem to be vulnerability factors in risk for PD. Apparently, all these
factors interact in complex ways over time. Future studies that examine the relation
between CO2 vulnerability, AS, and respiratory pathology in persons at risk for PD
may prove useful in determining possible underlying mechanisms.
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Individuals suffering from panic disorder experience recurrent and unexpected
panic attacks. Panic attacks are marked by fear and symptoms such as palpita-
tions and dyspnea. It has been established that genetic and familial influences
play an important role in the development of panic disorder. The objective of the
present thesis was to investigate a number of vulnerability factors in panic disorder
patients and their first-degree relatives. The factor COi sensitivity may identify
subjects with a predisposition to develop a panic disorder. Hence, we examined
whether COT sensitivity is a marker of a vulnerability to panic disorder. Further-
more, cognitive as well as physiological factors may play a role in explaining the
COi sensitivity. They were hypothesized to be important factors that might be
transmitted in panic disorder families. Accordingly, the role of anxiety sensitivity
and respiratory pathophysiology as vulnerability factors were investigated.
The 35% CO2 challenge is used to provoke panic-like symptoms in the labo-
ratory. A considerable amount of previous research has shown that panic disorder
patients are more vulnerable to 35% COT than other populations (see Introduction
Chapter 1). In Chapter 2, results showed that first-degree relatives of panic disor-
der patients, who had never experienced a panic attack, were also more reactive to
the 35% CO2 challenge than healthy control participants. This suggests that CO2
hypersensitivity may be a marker of a familial vulnerability to panic disorder.
The nature of the CO2 vulnerability, however, remains unclear. The cognitive
factor anxiety sensitivity may explain this vulnerability to CO2. Anxiety sensi-
tivity refers to individual differences in the fear of anxiety-related sensations and
the expectations that such sensations can have harmful consequences. The CO2
challenge may provoke sensations, feared by highly anxiety sensitive first-degree
relatives of panic disorder patients. Hence, it would be important to establish if
these first-degree relatives have elevated AS levels at all (Chapter 4). The results
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pointed out that first-degree relatives of panic disorder patients were more anxi-
ety sensitive than control participants, suggesting that anxiety sensitivity runs in
families.
As a methodological side issue, the influence of age and sex on anxiety sen-
sitivity levels was examined in Chapter 3. We found that neither age nor sex has
a clear influence on anxiety sensitivity in this particular sample of panic disorder
patients.
In Chapter 5, a study on a sub sample of first-degree relatives of panic disor-
der patients, namely children, was presented. Children of panic disorder patients
are most likely to be more at risk of developing panic disorder than older first-
degree relatives. Under the assumption that anxiety sensitivity is a risk factor for
the development of panic disorder, we studied whether they display higher levels
of anxiety sensitivity than control children. Somewhat unexpectedly, children of
panic disorder patients did not differ in anxiety sensitivity from control children.
Nevertheless, the possibility remains that anxiety sensitivity might be a develop-
ing vulnerability factor in children of panic disorder patients, that may increase
towards late adolescence or early adulthood.
We further elaborated on the theme of anxiety sensitivity in Chapter 6. Results
of this study showed a significant reduction of anxiety sensitivity levels in panic
disorder patients after treatment of a SSRI.
Research has repeatedly demonstrated an association between respiratory dis-
orders and panic. In Chapter 7, a study was presented on the prevalence of respi-
ratory disorders in panic disorder families. We found that first-degree relatives of
panic disorder patients reported significantly more chronic obstructive pulmonary
diseases in general and asthma in particular, than those of other anxiety disorder
patients. Given the fact that both asthma and panic disorder run in families, our
findings may suggest a specific association between the two disorders.
The link between respiratory pathology and panic disorder has been further
investigated in Chapter 8. The increased COT vulnerability displayed by panic
disorder patients may be related to lifetime respiratory pathology. Our results re-
vealed that panic disorder patients with a history of respiratory disorders were not
more anxious, did not show more panic symptoms, and did not have more panic
attacks after the CO: challenge than panic disorder patients without such a history.
It was concluded that a history of respiratory disorders is not a crucial factor in
CO2 vulnerability in panic disorder patients. This supports the idea that having a
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panic disorder is in itself an important factor in CO2 vulnerability.
The results of the studies in the present thesis indicate that COT sensitivity
seems to be a marker of a vulnerability to panic disorder. Furthermore, anxiety
sensitivity as well as respiratory pathology appear to be vulnerability factors in
risk for panic disorder. Apparently, all these factors interact in complex ways over
time (see Concluding remarks Chapter 9).
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Samenvatting
Mensen die lijden aan een paniekstoornis ervaren terugkerende en onverwachte
paniekaanvallen. Angst en Symptomen, zoals palpitaties en dyspneu zijn ken-
merken van een paniekaanval. Het is aangetoond dat genetische en familiale
invloeden een belangrijke rol speien in de ontwikkeling van een paniekstoornis.
Het doel van dit proefschrift was om een aantal kwetsbaarheidsfactoren in paniek-
patienten en hun eerstegraads familieleden te onderzoeken. De factor COi-gevoe-
ligheid kan mogelijk personen met een predispositie om een paniekstoornis te ont-
wikkelen, identificeren. Vandaar dat we onderzocht hebben of CO2-sensitiviteit
een marker is van een kwetsbaarheid voor een paniekstoornis. Verder kunnen
zowel cognitieve als fysiologische factoren een rol speien in het verklaren van
deze CCh-gevoeligheid. Deze factoren worden verondersfeld belangrijke ele-
menten te zijn die doorgegeven kunnen worden in families waarin paniekstoor-
nissen voorkomen. Hiermee in overeenstemming werden de rol van angstgevoe-
Iigheid (anxiety sensitivity) en respiratoire pathofysiologie als kwetsbaarheidsfac-
toren onderzocht.
De 35% CO2-provocatietest wordt gebruikt om paniekachtige Symptomen in
het laboratorium op te wekken. Een aanzienlijke hoeveelheid aan onderzoek heeft
aangetoond dat paniekpatienten gevoeliger zijn voor 35% COT dan andere po-
pulaties (zie Introductie Hoofdstuk 1). In Hoofdstuk 2 laten resultaten van een
experiment zien dat eerstegraads verwanten van paniekpatienten, die nooit een
paniekaanval hebben ervaren, ook meer reageren op de 35% CO2-provocatietest
dan gezonde controledeelnemers. Dit suggereert dat het zeer gevoelig zijn voor
35% CO2 een marker kan zijn voor een familiale kwetsbaarheid voor een paniek-
stoornis.
Echter de aard van de COi-gevoeligheid blijft onduidelijk. De cognitieve
factor angstgevoeligheid kan deze kwetsbaarheid voor COT misschien verklaren.
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Angstgevoeligheid venvijst naar individuele verschillen in de vrees voor angst-
gerelateerde sensaties en de verwachtingen dat zulke sensaties schadelijke con-
sequenties hebben. De CO2-provocatietest kan sensaties opwekken die hoog-
angstige eerstegraads familieleden van paniekpatienten vrezen. Daarom is het
belangrijk om eerst vast te stellen of eerstegraads verwanten überhaupt een ver-
hoogd niveau van angstgevoeligheid hebben (Hoofdstuk 4). De resultaten tonen
aan dat eerstegraads verwanten van paniekpatienten angstgevoeliger zijn dan con-
troledeelnemers. Dit suggereert dat angstgevoeligheid in de familie zit.
In Hoofdstuk 3 wordt de invloed van leeftijd en geslacht op angstgevoeligheid
onderzocht in een methodologisch georienteerde Studie. In deze steekproef van
paniekpatienten werd gevonden dat noch leeftijd, noch geslacht een duidelijke in-
vloed op angstgevoeligheid heeft.
In Hoofdstuk 5 wordt een studie beschreven over een subgroep van eerste-
graads familieleden van paniekpatienten, namelijk kinderen. Kinderen van paniek-
patienten hebben waarschijnlijk een hoger risico op het ontwikkelen van een pa-
niekstoornis dan oudere eerstegraads familieleden. Uitgaande van de assumptie dat
angstgevoeligheid een risicofactor is voor de ontwikkeling van een paniekstoornis,
onderzochten we of deze kinderen angstgevoeliger waren dan controlekinderen.
Enigszins onverwacht verschilden de kinderen van paniekpatienten niet in angst-
gevoeligheid van de controlekinderen. Desondanks blijft de mogelijkheid bestaan
dat angstgevoeligheid een kwetsbaarheidsfactor is die zieh nog ten voile kan ont-
wikkelen in de late adolescentie en vroege volwassenheid bij kinderen van paniek-
patienten.
De factor angstgevoeligheid wordt verder bestudeerd in Hoofdstuk 6. Resul-
taten van deze studie laten zien dat de angstgevoeligheid reduceert bij paniek-
patienten na behandeling met een SSRI.
Het is al herhaaldelijk aangetoond dat er een associatie bestaat tussen respira-
toire aandoeningen en paniek. Een studie over de prevalence van respiratoire aan-
doeningen in families met een paniekstoornis wordt in Hoofdstuk 7 beschreven.
We hebben gevonden dat eerstegraads verwanten van paniekpatienten in het al-
gemeen significant meer chronisch obstruetieve longaandoeningen, en specifiek
astma, hebben dan familieleden van patienten met een andere angststoornis. Ge-
geven het feit dat zowel astma als de paniekstoornis familiaal is. suggereren deze
bevindingen een specifieke associatie tussen beide aandoeningen.
De relatie tussen respiratoire pathologie en de paniekstoornis wordt verder on-
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derzocht in Hoofdstuk 8. De verhoogde CCh-gevoeligheid die paniekpatienten
vertonen kan gerelateerd zijn aan de respiratoire pathologie gedurende hun leven.
Onze resultaten laten zien dat paniekpatienten met een geschiedenis van respi-
ratoire aandoeningen niet angstiger reageren, niet meer panieksymptomen rap-
porteren, en niet meer paniekaanvallen hebben na een CO2~provocatietest dan
paniekpatienten zonder dergelijke geschiedenis. We kunnen hieruit concluderen
dat een geschiedenis van respiratoire aandoeningen geen cruciale factor is in de
CC>2-gevoeligheid van paniekpatienten. Dit ondersteunt het idee dat het hebben
van een paniekstoornis op zichzelf een belangrijke factor is in CCb-gevoeligheid.
De resultaten van de studies in dit proefschrift tonen dat CC>2-gevoeligheid
een marker kan zijn van een kwetsbaarheid voor een paniekstoornis. Daarenboven
lijken zowel angstgevoeligheid als respiratoire aandoeningen kwetsbaarheidsfac-
toren te zijn voor het risico op een paniekstoornis. Echter, alle eerdergenoemde
factoren staan vermoedelijk op complexe wijze met elkaar in wisselwerking (zie
Afsluitende opmerkingen Hoofdstuk 9).
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het vak wetenschappelijk onderzoeker geleerd. Ik wil u bedanken voor uw inspi-
rerende kijk op onderzoek. Ik ben blij dat ik van u geleerd heb om eerst de ruwe
data te visualiseren in grafieken alvorens statistische analyses erop los te laten.
Ook vond ik uw wetenschappelijke schrijfadviezen zeer waardevol. U gaf me
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wetenschap geleerd. Ik vond het prettig dat u me de gelegenheid gaf om onderzoek
te doen in Italie. Bij deze wil ik dan ook Giampaolo Perna en zijn gastvrije team
bedanken. Grazie!
Op een trein hoort ook een co-machinist en tijdens de reis, stapte dr. Schmers
op de rijdende trein. Koen, bedankt dat je mijn co-promotor en, zelfs in een hecti-
sche tijd, tijdelijk mijn duurste onderzoeksassistent ooit;-) wilde zijn. Ik waardeer
het dat ik mijn mening bij je kwijt kon.
De trein bolderde verder en af en toe stopte hij bij een tussenstation. Inmiddels
waren een aantal (ex)-collega's van het AAC ingestapt die ik graag bij naam ver-
noem. Mark Ahsmann, Marjan Böhm, Denise Cobben, Klara de Cort, Ann Goorts,
Marie-Jeanne Haack. Louis Kersten, Femmie Kruizinga, Jamie Luermans, Rudy
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Nijssen, Thea Overbeek, Julien Peeters, Henk Pols, Nicole Theunissen, Mariette
Ubaghs, Marlies van Duinen, Marijke van Kempen, Manuela Walraeven-Nix en
Francois Wilms, bedankt voor jullie medewerking en collegialiteit. Het zijn de
therapeuten en artsen die ervoor zorgdragen dat patienten weer met de trein durven
reizen. In het bijzonder wil ik Inge Leclaire en Nicolette Bongaerts bedanken voor
hun praktische assistentie bij de reis. Zonder jullie hulp zouden de studies in dit
proefschrift heel wat moeizamer tot stand zijn gekomen. En met dit over de jaren
heen uitgebreide team is er nog meer vlaai om van te smullen.
De trein werd steeds voller, want ook de onmisbare secretaresses van de ca-
paciteitsgroep en collega's van de universiteitsgang reisden mee. Met name Lea
Esten, Jolanda Koch, Ine Küsters en vooral Leni Noteborn, bedankt voor jullie
altijd vriendelijke service. Rob van Diest, bedankt voor het opzetten van onze in-
ternetfaciliteiten. Gelukkig was jij, als vrijwilliger, bereid de gang hiermee steeds
weer behulpzaam te zijn. Ik zal het geroep op de gang "wie zit er op het net" nog
bijna gaan missen.
Deze treinreis was een bijzondere periode in mijn leven en ik bedank mijn
vrienden die op de perrons voor me klaar stonden. In het bijzonder wil ik mijn
paranimfen Heidi Rijnen en Machteid Ouwens bedanken. Heidi, onze afspraken,
met name het zwemmen, deden en doen me altijd erg goed. Machteld, ik ben blij
dat ik al een hele tijd je vriendin mag zijn. Mijn ouders ben ik zeer dankbaar voor
hun onvoorwaardelijke steun vanaf het prille begin. Ingrid, zonder jou was deze
treinreis vast niet zo gezellig geweest. En, ik ben blij dat er telefoon bestaat.
Stephan, deze reis verliep een stuk vlotter met jou erbij. Ik waardeer het zeer
dat ik zoveel steun van je mocht ontvangen. Is de lay-out van dit boekje niet
prachtig .. .
De trein vermindert vaart. De bestemming is bereikt.
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